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Schematic depicting how a naturally occurring 
ligand-protein interaction is altered to create an 
OLRP. 
 
OLRP biosensors. (A) Pattern differentiation to 
identify similar compounds.  (B) Analyte 
concentration determination. 
 
Chemical complementation with (A) adenine 
selection, (B) histidine selection, and (C) β-
galactosidase screen.  For simplicity only one 
ACTR:GAD fusion protein is depicted.  
 
A) Targretin and B) LG335 
 
LG335 synthetic scheme 
 
NMR spectrum of LG335 
 
Mass spectrum of LG335 
 
(A) 9-cis retinoic acid, (B) LG335. 
 
Ligplot depiction of hydrophobic interactions 
between the RXR LBD and 9cRA.  Amino acids 
that are in helices are attached to corresponding 
coils.  The other amino acids are in loop regions.  
Amino acids mutated in this library are boxed.  
Coordinates are from 1FBY.pdb. 
  
Selection assay (SC -Ade -Trp -Leu plus ligand 
medium) for yeast growth in the presence of 9cRA 
(closed circles) and LG335 (open circles) for 43 
hours.  The 10-12 M point is actually 0 M ligand 
concentration. 
 
Screen assay (SC -Trp -Leu plus ligand  for β-
galactosidase activity with o-nitrophenyl β-D-
galactopyranoside (ONPG) in the presence of 9cRA 
(closed circles) and LG335 (open circles).  Miller 
units normalize the change in absorbance at 405 nm 
for the change in OD at 630 nm, which reflects the 
number of cells per well.  The 10-12 M point is 





























































































Activation of a leuciferase reporter in HEK 293 
cells by RXR variants in response to 9cRA (A) and 
LG335 (B).  Wt RXR (black circle), 
I268V;A272V;I310L;F313M (red inverted triangle), 
I268A;I310M;F313A;L436T (green square), 
I268A;I310S;F313A;L436F (yellow diamond), 
I268V;A272V;I310M;F313S;L436M (blue 
triangle), I268A;I310A;F313A;L436F (magenta 
octagon), and RXR:3Stop (cyan circle).  
 
Construction of pGBDRXR: 3stop. 
 
Construction of insert cassette library.  Asterisks 
indicate location of randomized codons. 
 
Schematic depicting increasing the activation 
threshold for chemical complementation.  Chemical 
complementation with adenine selection has a low 
activation threshold that allows growth (red line).  
A higher activation threshold (green line) is desired 
to increase the stringency of genetic selection, 
selecting against low efficacy RXR variants. 
 
Growth of transformants in variable stringency 
media. 
 
Selection assay (SC -Ade -Trp -Leu plus ligand 
medium) for yeast growth in the presence of 9cRA 
(black) and LG335 (red) for 48 hours. 
 
Screen assay (SC -Trp -Leu plus ligand medium) 
for β-galactosidase activity with o-nitrophenyl β-D-
galactopyranoside (ONPG) in the presence of 9cRA 
(black) and LG335 (red).  Miller units normalize the 
change in absorbance at 405 nm for the change in 
optical density at 630 nm, which reflects the 
number of cells per well. 
 
(A)Wild type RXR crystal structure with 9cRA and 
LG335 docked into (B) 
I268V;A272V;I310L;F313M, (C) 
I268M;I310V;F313L;L436A, and (D) 
A271S;A272T;I310S;F313L;L436A. 
 
No correlation is found between binding pocket 




























































































γ-oxo-1-pyrenebutyric acid (OPBA). 
 
Activation of 10 RXR variants by OPBA. 
 
Selection (A) and screening (B) of RXR variants 
A272S;I310V;F313M and A272T;I310L;F313T.  
The variants were grown in SC -Ade -Trp -Leu (A) 
or SC -Trp -Leu (B) medium with increasing 
concentrations of 9cRA (dark blue) or OPBA (light 
blue). 
 
Structures generated by docking calculations for (A) 
A272S;I310V;F313M and (B) 
A272T:I301L;F313T. 
 
LG335 quantification standard curve.  Trial 1 (red 
circles) and Trial 2 (blue squares) were fitted with 
linear regression lines (red and blue respectively).  
Trail 1 sample (open circle) and Trial 2 sample 
(closed square). 
 
Sequence changes between wild-type RXR and 
I268A;A272V;G304V;F313M;∆13 
 
A) Selection and B) screening experiments for 

























































3AT  3-amino-1,2,4-triazole 
9cRA  9-cis retinoic acid 
ABC  ATP-binding cassette 
ACTR  Human activator for thyroid and retinoid receptors 
Ade  Adenine 
A  Alanine 
ADMET Absorption, distribution, metabolism, excretion, and toxicology 
AmB  Amphotericin B 
AUC   Area under the curve 
CVFF  Consistent valence forcefield 
DBD  DNA binding domain 
DTP  Developmental Therapeutics Program 
Eff  Efficacy 
EMS  Ethyl methane sulfonate 
F  Phenylalanine 
FEP  Free energy perturbation 
GAD  Gal4 activation domain 
GBD  Gal4 DNA binding domain 
HPLC  High-performance liquid chromatography 
I  Isoleucine 
L  Leucine 
LBD  Ligand binding domain 
xii 
LC  Liquid chromatography 
Leu  Leucine 
M  Methionine 
MMC  Metropolis Monte-Carlo 
MRM  Multiple reaction monitoring 
MS  Mass spectrometry 
OLRP  orthogonal ligand-receptor pair 
ONPG  o-nitrophenyl β-D-galactopyranoside 
OPBA  γ-oxo-1-pyrenebutyric acid 
PBN  Polymyxin B nonapeptide 
RE  Response element 
RMSD  Root mean squared deviation 
RXR  Human retinoid X receptor-α 
S  Serine 
SA  Simulated annealing 
SC  Synthetic complete 
T  Threonine 
Trp  Tryptophan 
V  Valine 







Creating receptors for control of transcription with arbitrary small molecules has 
widespread applications including gene therapy, biosensors, and enzyme engineering.   
Using the combination of high throughput docking, codon randomization, and chemical 
complementation, we have created new receptors to control transcription with small 
molecules.  Chemical complementation, a new method of protein engineering, was used 
to discover retinoid X receptors (RXR) variants that are activated by compounds that do 
not activate wild-type RXR.   
A first library of 32,768 RXR variants was designed for the synthetic retinoid-like 
compound LG335.  The library produced ligand-receptor pairs with LG335 that have a 
variety of EC50s and efficacies.  One engineered variant has essentially the reverse ligand 
specificity of wild-type RXR and is transcriptionally active at 10-fold lower LG335 
concentration than wild-type RXR with 9cRA in yeast.  The activity of this variant in 
mammalian cells correlates with its activity in yeast.   
A second library of 262,144 RXR variants was designed for two purposes: (i) to 
develop a high-throughput chemical complementation method to select variants that have 
high efficacies and low EC50s; and (ii) to find variants which are activated by small 
molecules not known to bind RXR variants.  Selection conditions were manipulated to 
find only variants with high efficacies and low EC50s.  This library was also selected for 
variants that activate transcription specifically in response to γ-oxo-1-pyrenebutyric acid 
(OPBA), which is different from any known RXR ligand.  OPBA was chosen as a 
potential ligand using high-throughput docking with the software program FlexX.  Two 
variants are activated by OPBA with an EC50 of 5 µM.  This is only ten-fold greater than 
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the EC50 of wild type RXR with its ligand 9cRA (500 nM) in yeast.   
An improved method synthesizing LG335 and a method for quantifying 
intracellular ligand concentrations were developed.  Although the LG335 synthetic 
method has an additional step, the overall yield was improved to 8% from 4% in the 
original publication.  Liquid chromatography and mass spectrometry was used to quantify 
the intracellular concentration of LG335, which was found to be within four fold of the 








Orthogonal Ligand-Receptor Pairs 
 Interactions between small molecules and proteins are ubiquitous in nature.  
These interactions are involved in biological processes ranging from signal transduction 
by phosphates to hormones regulating gene expression.  Manipulating naturally occurring 
small molecule-protein interactions can lead to the creation of orthogonal ligand-receptor 
pairs (OLRP).  An orthogonal ligand-receptor pair occurs when a protein is mutated to 
bind a new, synthetic ligand and no longer binds its natural ligand.  Thus, the mutated 




Figure 1.1  Schematic depicting how a 
naturally occurring ligand-protein 
interaction is altered to create an OLRP.
2 
Orthogonal ligand-receptor pairs offer the ability to control transcription with 
small, drug-like molecules.  Controlling transcription with exogenous small molecules 
would provide powerful tools for research and a variety of practical applications.  For 
example, genome projects have revealed tens of thousands of genes with unknown 
functions.  Orthogonal ligand-receptor pairs controlling transcription could be used to 
study the function of these genes by redirecting the receptor to bind near the promoter of 
the gene, delivering the gene for the orthogonal receptor to the cell or animal, and 
activating transcription of the target gene at the desired time by adding the orthogonal 
ligand.  If transcription of a set of genes in a cell line or animal were under the control of 
multiple ligand-receptor pairs, simply applying the appropriate cocktail of ligands could 
control multiple genes.  Indeed, the levels of expression of each gene could be titrated, 
not only turned just on or off. 
A general method of activating transcription with small molecules would provide 
useful research tools for creating conditional knockout cell lines and animals.  Genetic 
knockouts can result in embryonic lethality, which does not allow the gene function in a 
mature organism to be studied.  Spatio-temporal control of gene expression through 
orthogonal ligand-receptor pairs would allow researchers to stop or start the expression of 
a gene at any point in development.  This conditional gene expression would give a better 
picture of the gene’s function and be useful in elucidating signal transduction pathways. 
For practical applications, orthogonal ligand-receptor pairs controlling transcription have 
a potentially profound impact for gene therapy.  The orthogonal receptor could be 
directed to activate a gene at its natural locus in the genome that would address the cause 
of the disease or induce apoptosis to kill the diseased cell.  Another possibility for gene 
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therapy is that the orthogonal ligand-receptor pair can be used to control the expression of 
another delivered therapeutic gene (e.g. CFTR for cystic fibrosis).  When the therapeutic 
gene is delivered, the gene for the orthogonal receptor would be delivered with it.  The 
receptor would be expressed under a cell-type specific promoter, bind to the synthetic 
promoter for the therapeutic gene, and express the therapeutic gene to the desired level by 
the appropriate dose of the orthogonal ligand.  This could potentially circumvent a 
current problem with gene therapy - controlling the amount of expression of the 
therapeutic protein.  Under the described control, if a low efficiency of gene delivery is 
achieved, then the appropriate amount of protein can be achieved by increasing the dose 
of the orthogonal ligand (within limits).  Alternatively, administering a low ligand 
concentration would compensate for efficient gene delivery. 
Agricultural applications of orthogonal ligand-nuclear receptor pairs include 
conditional expression of any RNA or protein, including short interfering RNAs to block 
gene expression, human vaccine proteins, insecticidal proteins, and disease resistance 
genes.  Expressing insecticidal proteins and disease resistance genes only at specific 
times (rather than constitutively) would likely decrease the occurrence of resistance 
developing in the environment. 
Additionally, OLRPs could be used to activate transcription of a reporter gene and 
therefore, serve as biosensors for small organic compounds.  Arrays of OLRP biosensors 
that are activated by a variety of small molecules could be used to discriminate between 
similar compounds based on the pattern of activation (Figure 1.2A).  Also, analyte 
concentration could be determined using arrays of OLRPs that have increasing KD’s for 
the analyte (Figure 1.2B).  Finally, OLRPs could be engineered to bind the desired 
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product of an enzymatic reaction.  A clone from a library of engineered enzymes that 
produces the desired product would activate transcription of the reporter gene, thereby 
identifying the cell that contains the desired enzyme.  The gene for this enzyme could 
then be recovered. 
 
Creation of Orthogonal Ligand-Receptor Pairs 
Traditionally, OLRPs are created using site-directed mutagenesis to alter the 
interactions in the binding pocket.  Several strategies have been used including steric 
complementation, electrostatic interaction reversal, and hydrophobic interaction 
manipulation [1]. 
The steric complementation strategy is often referred to as “bumps and holes” [2].  
This approach involves mutating a large amino acid in the binding pocket of the receptor 
to create a “hole”, which is complemented by the addition of an additional functional 
group or “bump” on the ligand.  The Schreiber and Shokat groups have used this 
A            B 
                     
 
Figure 1.2  OLRP biosensors. (A) Pattern differentiation to identify similar 
compounds.  (B) Analyte concentration determination. 
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approach to engineer cyclophilin / cyclosporin and myosin-Iβ / ATP interactions, 
respectively [2, 3].  Schreiber and coworkers synthesized a cyclosporin dervative that was 
able to bind cyclophilin variants with high affinity.  These ligand-receptor pairs were 
created as chemical inducers of dimerization to study protein-protein interactions and 
signal transduction [2].  Shokat and coworkers synthesized N6-(2-methylbutyl) ADP, 
which selectively inhibits the Y61G variant of myosin-Iβ over wild type myosin-Iβ [3].  
This ligand-receptor pair was used to determine that myosin-Iβ participates in hair cell 
adaptation [4].    One major downfall of using bumps and holes is that the modified 
receptors often retain significant affinity for the wild-type ligand.  Although not all 
applications require that the receptor not bind the wild-type ligand, these receptors cannot 
be defined as orthogonal. 
Researchers have had more success using strategies that alter electrostatic 
interactions.  Hwang and Miller were pioneers in this area.  They changed the specificity 
of E. coli elongation factor Tu from guanosine 5’-diphosphate (GDP) to xanthosine 5’-
diphosphate (XDP) with a single amino acid change [5].  The mutation of aspartate, 
which normally forms a salt bridge with the amine at the 2 position of GDP, to 
asparagine allows hydrogen bonding with the 2-position carbonyl of XDP resulting in the 
reversal of a hydrogen bond.  Because the salt bridge with GDP can no longer occur, 
orthogonality is introduced.   
Charge reversal has also been used to create OLRPs.  The Koh group made a 
serine to aspartic acid mutation in the retinoic acid receptor (RAR), which bound a 
positively charged retinol derivative and not the negatively charged all-trans-retinoic acid 
(atRA) [6].  However, the transcriptional activation by this variant nuclear receptor was 
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greatly reduced versus wild type RAR with atRA.  Hwang and Warshel suggest that 
charge reversal will never produce variants that have wild-type-like activity because 
these interactions are stabilized by more than the amino acids in the immediate vicinity of 
the salt bridge.  Altering only local residues leaves these other interactions intact and 
does not afford additional stability to the reversed salt bridge [7]. 
Altering hydrophobic interactions is another strategy for creating OLRPs.  Doyle 
and coworkers used site directed mutagenesis to make a series of single, double, and 
triple mutations in the binding pocket of the retinoid X receptor (RXR) [8].  These 
variants were screened against several drug-like compounds.  One variant 
Q275C;I310M;F313I is not significantly activated by 9-cis retinoic acid, a ligand for the 
wild type receptor, but is activated by LG335, a compound that does not activate wild-
type RXR and is, therefore, functionally orthogonal. 
Site directed mutagenesis and rational design of mutations have generated OLRPs 
with moderate success.  This process, however, is labor intensive with little return on the 
investment.  This dissertation presents a new strategy for creating and discovering 
OLRPs.  Large libraries of RXR variants were created using structure-based codon 
randomization and chemical complementation, a genetic selection system, was used to 
find the variants activated by specific small molecules.   
 
Libraries 
 Libraries of proteins can be constructed to create proteins with altered affinity.  In 
addition to finding new OLRPs, the distribution of amino acids in functional proteins can 
provide information about the importance of individual residue positions and the 
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requirement for side chain volume, polarity, and charge.  There are three primary 
methods for creating protein libraries: random mutagenesis, gene shuffling, and structure-
based randomization.   
 Random mutagenesis can be accomplished by both enzymatic and chemical 
methods.  Error prone PCR, an enzymatic method, uses low fidelity DNA polymerases to 
make random mutations [9].  Varying ion and dNTP concentration, and annealing 
temperature influences the rate of incorrect base incorporation [10-12].  Chemical 
methods of random mutagenesis involve incubating the gene of interest with chemicals 
like hydroxylamine, bisulfate, and ethyl methane sulfonate (EMS) [13, 14].  Chemical 
methods tend to be less biased than enzymatic methods, which favor AT to GC changes 
[15-17].  Random mutagenesis methods do not take advantage of any structural or 
functional information known about the protein.  Alternatively, these methods do not 
require any structural or functional information. 
 Gene shuffling techniques involve mixing and matching portions of two or more 
proteins to create libraries.  DNA shuffling, developed by Stemmer [18, 19], and its 
multiple adaptations and improvements [20-24] rely on the same basic steps.  First, two 
or more genes are cut into small pieces.  These pieces are then randomly reassembled and 
PCR is used to amplify the pieces that are the correct length.  The pieces are then cloned 
into an expression vector, expressed, and assayed for function.  The set of shuffled genes 
can range from the same gene with varying mutations, to homologous genes with 
different functions, to completely unrelated genes.  The concept behind directed 
evolution is to use “Nature's” solutions to find solutions for new problems in a short 
amount of time.  Although the structure and function of the parent protein is considered 
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when selecting genes to shuffle, this approach does not take advantage of specific 
information to create proteins with a specific function. 
 Structure-based randomization, however, does consider structure and function in 
the design of the library.  Using this method, specific amino acids can be randomized to 
either a small subset of amino acids or to all 20 amino acids [25].  Depending on the 
experiment, some amino acids may be eliminated due to charge, polarity, hydrophobicity, 
or side chain volume.  Residue positions can be chosen based on location in the protein or 
potential to alter function and binding affinity.  Lim and Sauer used this method to 
investigate the packing of the hydrophobic core of the λ repressor [26, 27].  After 
selection of functional variants, the composition of amino acids can be analyzed to 
determine the amino acid property requirements at each randomized position.  This 
method could also be used to extend alanine scanning and obtain information about the 
importance of side chain size, polarity, and charge at individual amino acid positions. 
 
Retinoid X Receptor 
 The human retinoid X receptor α (RXR) is a ligand-activated transcription factor 
of the nuclear receptor superfamily.  RXR plays an important role in morphogenesis and 
differentiation and serves as a dimerization partner for other nuclear receptors [28].  Like 
most nuclear receptors, RXR has two structural domains, the DNA-binding domain 
(DBD) and the ligand-binding domain (LBD), which are connected by a flexible hinge 
region.  The DBD contains two zinc modules, which, when two RXRs homodimerize, 
bind a direct repeat of six bases with a one base spacer (TAGGTCA A AGGTCA GT 
AGGTCA A AGGTCA G (CRBPII)) [29, 30].  The LBD binds and activates 
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transcription in response to multiple ligands including phytanic acid, docosahexanoic 
acid, and 9-cis retinoic acid (9cRA) [31-33] .  RXR is a modular protein; the DBD and 
LBD function independently.  Therefore, the LBD can be fused to other DBDs and retain 
function.  A conformational change is induced in the LBD upon ligand binding initiating 
recruitment of coactivators, which have histone acetyltransferase (HAT) activity [34], 
and the basal transcription machinery resulting in transcription of the target gene [35]. 
 Nuclear receptors have evolved to bind and activate transcription in response to a 
variety of small-molecule ligands.  The known ligands for nuclear receptors are 
chemically diverse and include steroid and thyroid hormones, vitamin D, prostaglandins, 
fatty acids, leukotrienes, retinoids, antibiotics, and other xenobiotics.  Evolutionarily 
closely related receptors (e.g. thyroid hormone receptor and retinoic acid receptor) bind 
different ligands, whereas some members of distant subfamilies (e.g. RXR and retinoic 
acid receptor) bind the same ligand [36].  This diversity of ligand-receptor interactions 
demonstrates the versatility of the fold for ligand binding and suggests that it should be 
possible to engineer LBDs with a large range of novel selectivities.   
 
Chemical Complementation 
Chemical complementation is a three-component genetic selection system in 
which the survival of S. cerevisiae is linked to ligand activation of the nuclear receptor 
RXR (Figure 1.2A).  The PJ69-4A strain has been engineered with an ADE2 gene under 
the control of a Gal4 response element (RE) [37].  The Gal4 DNA binding domain 
(DBD) and the RXR ligand binding domain (LBD) fusion protein binds the Gal4 RE.  












Figure 1.3  Chemical complementation with (A) adenine 
selection, (B) histidine selection, and (C) β-galactosidase screen.  
For simplicity only one ACTR:GAD fusion protein is depicted.  
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activation domain (GAD) is also expressed. Only in the presence of ligand does ACTR 
bind the RXR LBD.  This event allows transcription of the ADE2 gene, adenine 
production, and therefore, yeast survival on media lacking adenine [38, 39]. 
The PJ69-4A strain also has the HIS3 and LacZ genes under the control of Gal4 
response elements (Figure 1.3B and C).  The HIS3 gene encodes the enzyme imidazole 
glycerolphosphate dehydratase, which is inhibited by 3-amino-1,2,4-triazole.  This 
inhibition allows for a variable stringency chemical complementation.  The LacZ gene 
encodes β-galactosidase, which hydrolyzes o-nitrophenyl-galctopyranoside (ONPG) into 
galactose and o-nitrophenol, a yellow compound.  This color change affords an assay to 
quantify transcriptional activation more directly than the growth assays with the ADE2 
and HIS3 genes.    
 Chemical complementation is useful for selecting functional variants from large 
libraries of receptors.  Traditionally, a library is evaluated using a screen in which each 
member of the library is tested individually for a specific function.  This technique 
requires that each library member be spatially separated before initial evaluation.  
Because chemical complementation is a genetic selection system, large libraries are 
evaluated for function in a single experiment before they are spatially separated.  The 
libraries are grown on selective media containing a potential ligand or ligands.  The cells 
that contain a receptor for the ligand are able to survive and form colonies.  These 
colonies can then be spatially separated and further evaluated using additional selection 
and/or screen assays.  Typically, 0.1% or less of the total library survives the initial round 
of chemical complementation, therefore larger libraries can be evaluated with a fraction 
of the time, energy, and cost associated with traditional screening methods. 
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Docking Calculations 
 Molecular modeling was used to generate hypotheses concerning ligand-receptor 
interactions.  Two software programs were used: Affinity and FlexX. 
 
Affinity 
 Affinity is a module of the Insight II (Accelrys) software family.  This program 
uses a two step method of Monte Carlo simulation followed by simulated annealing to 
generate possible binding modes of a ligand in a protein’s binding pocket.  Affinity was 
chosen to complete in silico binding calculations of ligand-receptor pairs for two reasons: 
(1) it allows flexibility of both the ligand and the amino acids in the binding pocket, and 
(2) it uses a true force field as opposed to a simpler scoring function.   
A general method was developed for docking ligands into the binding pocket of 
the RXRα LBD crystal structure (1FBY) [40].  After obtaining the coordinates of the 
crystal structure from the Protein Databank, the structure must be prepared for docking.  
The crystal structure contains two RXR LBDs; the A chain was used exclusively in these 
studies∗.  The A chain and its associated water molecules and 9cRA were unmerged from 
the total structure.  Hydrogen atoms were added to all three molecule sets using a pH of 
7.4 to determine the charge state of amino acid side chains.  InsightII compares the pH of 
the “solution” with templates of amino acid charge states and associated pKa’s.  If the 
                                                 
∗ The root mean squared deviation (RMSD) between all atoms of the A and B chains is 0.94 Å.  
The RMSD for the backbone atoms is 0.60 Å.  The only large deviation between the backbone 
atoms occurs in the loop between helices nine and ten.  There are also side chain conformational 
differences on the exterior of the structure and the B chain is missing residues 224 through 228. 
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amino acid and pH match a template then the charge state and appropriate hydrogens are 
assigned.  If there is no match, the amino acid is assigned a neutral charge.  The 
crystallographic water was oriented through energy minimization using the steepest 
descents and conjugate gradient algorithms.  The protein was finally “soaked” in a 5 Å 
layer of water so that the docking is performed in explicit solvent.  Soaking is 
accomplished by placing the protein in the center of an equilibrated box of water 
followed by removing water molecules that either contact atoms in the protein or are 
further than 5 Å from the protein.   
Potentials are assigned to the atoms using the consistent valence force field 
(CVFF) [41], which is used to calculate atom-atom interactions. This all-atom force field 
was parameterized for common protein and small molecule functional groups and was 
shown to reproduce the crystal structure of dihydrofolate reductase with trimethoprim 
bound better than a united-atom force field [41].  Atom types are assigned based on 
hybridization and functional group or amino acid participation.  Partial and formal 
charges are assigned based on CVFF’s table of atom types and associated charges. 















































The first nine terms describe vibrations of internal coordinates including: (1) bond 
stretching, (2) angle bending, (3) torsional rotation, (4) out-of-plane bending, and (5-9) 
combinations of the previous terms.  Term ten accounts for van der Waals interactions 
(1.1) 
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and term eleven accounts for electrostatic interactions.   
For docking, the ligand is manually placed in the binding site of the protein by 
superimposing atoms of the ligand to be docked onto atoms of the crystallographic 9cRA.  
The amino acids within 6 Å of the placed ligand are defined as the “binding site”.  
Therefore, any amino acid with at least on atom within 6 Å of one atom of the ligand is 
allowed to move.  Hydrogen bond donor and acceptor atoms are defined for both the 
ligand and atoms within 5 Å of the placed ligand.  Torsions around which the rotation is 
allowed are also defined for the ligand.   
A Monte Carlo simulation is used to generate possible binding modes of the 
ligand-protein pair.  The placed ligand is first energy minimized using the conjugate 
gradient method for a defined number of steps.  Non-bonding interactions are calculated 
using a repulsive bounded quartic potential for van der Waals interactions with 
coulombic interactions set to zero.  This function is used for the initial searching because 
it minimizes the chance that the minimization will terminate when there are many 
undesirable contacts, while allowing for approximate placement of the ligand in the 
binding pocket.  After initial minimization, the ligand is randomly translated and rotated 
in the x, y, and z dimensions and the torsions are rotated to generate a new, random 
ligand placement.  The resulting structure is minimized and the energy of the new 
structure is compared to the previous structure.  If the energy of the new structure is 
lower than the energy of the previous structure, the new structure is accepted.  If the 
energy of the new structure is greater than the energy of the previous structure, it will be 
accepted if the energy is within a predefined energy range or the Boltzmann factor is 
greater than a random number between 0 and 1.  The Boltzmann factor is calculated using 
15 








new −−  
where V(rN) is the potential energy (V) of each position (rN) for N particles in the system, 
kB is the Boltzmann constant and T is the temperature.  Using the Boltzmann factor as the 
criterion for structure acceptance in a Monte Carlo simulation is termed Metropolis 
Monte Carlo (MMC) [42].  This procedure permits small uphill moves in which the 
smaller the uphill move, the greater the probability the move will be accepted.  Up to 
twenty accepted structures are generated and the ten with the lowest energy are kept. 
Following the Monte Carlo simulation, simulated annealing (SA) is used to refine 
each of the best structures.  The SA process simulates heating the protein-ligand complex 
to 500 K and slowly cooling to 300K.  At each incremental temperature drop, the system 
is allowed to reach thermal equilibrium    The purpose of simulated annealing is to find 
the global minimum of the structure by adding potential energy to the system to allow the 
complex to overcome small energy barriers.   
The electrostatic interactions in the SA are calculated using the cell multipole 
method [43-46].  Using this method, a box containing all the atoms is divided into 
uniform, cubic cells.  The multipole moment is then calculated for each cell as a sum of 
the moments of all the atoms in the cell.  Next, the interactions between each cell and the 
26 cells directly surrounding each cell are calculated explicitly using Coulomb’s Law.  
For cells outside the initial 27 cells, the interactions are calculated using a Taylor series 
multipole expansion.  For greater efficiency in calculating the Taylor series coefficients, 
cells are grouped into larger and larger cells as the distance increase from the initial 27 
(1.2) 
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cells increases.  This grouping of cells allows the time required to scale linearly with N, 
rather than N2 with the standard Ewald method [47], thereby decreasing the calculation 
time. 
The final step is to calculate the ligand-receptor interaction energies for each 
accepted and minimized structure.  Discover is used to calculate the total energy of the 
protein-ligand complex, the energies of the protein and the ligand individually, and the 
interaction energy between the protein and ligand.  The protein-ligand interaction energy 
is separated into the van der Waals and electrostatic contributions.  These energies can be 
used to compare the docked structures.  However, the force field does not include 
desolvation terms.  Affinity® also does not allow for any global protein conformational 
changes.  These deficiencies must be considered when comparing energies between 
different ligand-receptor pairs.  
 
FlexX 
 FlexX is a software program developed for automatic, high-throughput docking 
[48].  This program was used to dock libraries of compounds into the RXR LBD binding 
pocket.  FlexX was chosen for this purpose because it is optimized for ligand-protein 
docking, has high-throughput capability, and allows ligand flexibility.  However, FlexX 
does not allow the protein to be flexible and it uses a scoring function.  These were 
determined to be essential compromises required to decrease docking time. 
 The A chain of the RXR LBD [40] was prepared using InsightII.  The A chain 
was unmerged from the whole crystal structure and hydrogens were added at a pH of 7.4 
with charged C- and N-termini.  This structure was saved in .pdb format and used to 
17 
create the pocket and surface descriptor files for FlexX using a receptor description file 
and the associated FlexX commands.  The coordinates for each ligand must be in a 
separate SYBYL mol2 files with three-dimensional coordinates, the correct bond types, 
and hydrogens added.  All of these steps were performed using the InsightII Biopolymer 
and Builder modules.    
 FlexX uses a scoring function for estimation of binding free energy of docked 
ligand-protein complexes.  This ∆G value is used to rank the docked solutions.  The 



































and is based on a scoring function developed by Böhm [49].  ∆R and ∆α are the 
deviations of the interactions from the ideal distances and angles.  The f(∆R,∆α) function 









































These functions are designed to penalize interactions that are outside the ideal interaction 













addition of terms for aromatic and lipophilic interactions.  The aromatic interaction term 
uses the same f(∆R,∆α) as the other interactions, however this function proved to be 







































Rf       
where ∆R is the difference between the actual atom distances plus 0.3 Å and the ideal 
atom distance (the sum of the van der Waals radii of both atoms) plus 0.3 Å.  Table 1.1 
lists default ∆G values. 
 FlexX uses an incremental construction algorithm to dock the ligand into the 
receptor’s binding pocket.  This method involves three steps: (1) base fragment selection, 
(2) base fragment placement, and (3) complex construction.   
 For high-throughput applications base fragment selection is performed 
automatically [50].  Base fragment selection begins by cutting the ligand at all acyclic 
rotatable bonds to create components.  These components are then combined to create 
(1.5) 
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fragments suitable for placement.  A good fragment is defined as one that is both 
placeable and specific.  The authors define placeability of a fragment as having enough 
interaction sites, but not too many conformations and define specificity of a fragment as 
having interaction sites that are complementary to the binding pocket.  A scoring function 
is used to choose a set of fragments with the maximum number (up to four) of hydrogen 
bonds and salt bridges (nric), the maximum number (up to six) of hydrophobic 
interactions (nic), and the minimum number of conformations (nc): 
cicriccicricbs n)6,nmin(100)4,nmin(1000)n,n,n(f −+=  
Fragments must also adhere to the following rules: (1) a base fragment must not be fully 
contained in another fragment, (2) a component cannot be in more than two base 
fragments, and (3) a base fragment must be necessary for connectivity or have interaction 
centers. 
The second step in docking is base placement [51].  First, interaction centers and 
surfaces are defined for the base fragment atoms and the protein atoms in the binding 
pockets.  An interaction center is defined as the center of an atom.  An interaction surface 
shape and distance from the interaction center is defined by the type and hybridization of 
the atom and its participation in a functional group.  Next, three interaction centers from 
the ligand are superimposed onto three compatible interaction surfaces of the binding 
pocket and vice versa.  Then the root-mean squared (rms) deviation between placements 
is calculated and fragments are clustered based on a predefined threshold.  All fragment 
placements within the defined rms threshold are merged into one placement.  Finally, the 
fragment placements are ranked using the scoring function. 
The final docking step is complex construction [48]. First, a new fragment is 
(1.6) 
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added to all fragment placements in all possible conformations.  Next, the new fragment 
placements are evaluated for overlap with the receptor.  A cubic grid is drawn in the 
three-dimensional space covering the binding pocket and spheres with radii equal to the 
van der Waals radius of each atom plus the van der Waals radius of the largest atom in 
the receptor are drawn around the atoms of the ligand.  The cubes that intersect the sphere 
are checked for receptor atoms.  If the atoms in the intersecting cubes are too close, the 
ligand atom will be moved away and if the atoms are too far away, the ligand atoms will 
be moved closer to optimize the interaction.  The optimized fragment placements are then 
clustered to remove redundant placements.  Finally, these new fragment placements are 
ranked with the scoring function.  Complex construction continues by adding another 
fragment and repeating the optimization until the whole ligand is assembled.  
 When the docking is complete, FlexX outputs a specified number of placements 
with their energies and three-dimensional coordinates.  It should be noted that although 
the energies are given in kcal/mole, a scoring function is used to calculate these energies, 
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Ligand Pharmaceuticals, in the search for RXR selective agonists, synthesized a 
series of compounds that produced Targretin® (Figure 2.1A).  Targretin® is an RXR 
agonist that is FDA approved to treat cutaneous T-cell lymphoma and AIDS related 
Kaposi’s sarcoma.  LG335 (Figure 2.1B) was synthesized as a part of this study and did 
not bind or activate any RXR subtype [1].  Doyle and coworkers found that the RXR 
variant Q275C;I310M;F313I was activated by LG335, but not by 9cRA [2]. 
To continue these studies and to find new ligand-receptor pairs, it was necessary 
to synthesize more LG335.  After attempting the published synthesis, the correct product 
of the second reaction, which has a published yield of 8% [1] could not be isolated.  An 
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Figure 2.2  LG335 synthetic scheme 
coupled 2,5-dimethylehexanediol and benzene to produce 1 [3].  A Friedel-Crafts 
acylation with propionyl chloride, produced 2 [4, 5].  The carbonyl was reduced with 
hydrogenation and the product, 3 [6], was coupled to 4 using Friedel-Crafts acylation.  
Finally, the ester was hydrolyzed to a carboxylic acid using 5M KOH, producing LG335 
[1].  This synthetic route has five steps with an overall yield of 8% [7], which is better 
than the original published yield of 4% [1].  Optimization could further increase the 
overall yield of the new synthetic route. 
Mass spectrometry, NMR, and elemental analysis were used to verify the identity 
and purity of LG335.  The 1H NMR (CDCl3) (Figure 2.3) spectrum showed peaks with 
the following chemical shifts: δ 0.88 (t, 3H, -CH2CH2CH3), 1.20 (s, 6H, CH3), 1.32 (s, 
6H, CH3), 1.55 (dt, 2H, -CH2CH2CH3), 1.69 (s, 4H, CH2), 2.65 (t, 2H, -CH2CH2CH3), 
7.20 (s, 1H, Ar-CH) 7.23 (s, 1H, Ar-CH), 7.89 (d, 2H, Ar-CH), 8.18 (d, 2H, Ar-CH).  The 
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electron ionization mass spectrum (Figure 2.4) has major peaks corresponding to the 
molecular ion and four fragment ions (Table 2.1) consistent with the structure of LG335.  
High-resolution mass spectrometry found an accurate mass of 378.2195 amu, which 
differs from the calculated mass of 378.2189 amu by 1.6 ppm.  Elemental analysis of 
LG335 found that the LG335 sample submitted is 79.10% C and 7.96% H, which is 
consistent with the calculated 79.33% C and 7.99% H. 
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Figure 2.4 Mass spectrum of LG335 
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Table 2.1  Mass Spectrum Ions 




















Materials and Methods 
3-(1-Carbonyl)propyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronapthylene (2) 
2,5-dimethyl-2,5,hexanediol (5.0 g, 34 mmol) was dissolved in anhydrous 
benzene (150 mL).  AlCl3 (5.0 g, 38 mmol) was added slowly while the mixture was 
stirred in an ice bath, followed by stirring at room temperature for 1 hour.  Another 
portion of AlCl3 (5.0 g, 38 mmol) was then added and the reaction was heated to 50 °C 
and stirred overnight.  The brown solution was poured over iced 0.4 M HCl (50 mL) and 
extracted with ether (3 x 50 mL).  The organic layer was then sequentially washed with 
water, saturated aqueous NaHCO3, and brine (80 mL each) and dried (MgSO4).  The 
solvent was removed in vacuo to afford 6.2 g of a yellow liquid [3].  
 The crude product was then mixed with propionyl chloride (3.2 mL, 37 mmol) 
and the resulting solution added dropwise to a mixture of AlCl3 (5.0g, 38 mmol) in 
dichloroethane (20 mL) while maintaining the temperature between 20 and 25 °C.  The 
mixture was stirred for 2 hours at room temperature, at which point it was quenched by 
pouring carefully over ice.  The reaction mixture was then extracted with methylene 
chloride (3 x 10 mL).  The organic layers were then combined, washed with water and 
saturated aqueous NaHCO3, and the volatiles removed by rotary evaporation.  The 
product was purified by silica gel column chromatography eluting with 
hexanes:chloroform (4:1, then 1:1) to yield 6.9 g (28 mmol, 73%) of product as a yellow 
oil [4, 5].   
 
3-Propyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronapthylene (3) 
3-(1-Carbonyl)propyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronapthylene (1.0 g, 4.1 mmol) 
32 
in MeOH (10 mL), H2O (1 mL), and conc. HCl (3 drops) was treated with 10% Pd/C 
(144 mg) and subjected to catalytic hydrogenation conditions at 60 psi while heating 
gently overnight.  When the reaction was considered complete (Rf = 0.76, 5% EtOAc in 
hexanes) it was filtered through a celite pad and rinsed with MeOH (10 mL) and hexane 
(50 mL).  Water (1 mL) was then added to the filtrate and the organic phase separated 
and washed with brine (2 x 20 mL).  The aqueous layer was washed with hexanes (2 x 20 
mL).  The organic layers were dried (Na2SO4), filtered and the volatiles removed by 
rotary evaporation to produce 510 mg (2.2 mmol, 54%) of a colorless oil [6]. 
 
4-[(3-Propyl-5,5,8,8-tetramethyl –5,6,7,8-tetrahydro-2-naphtyl)carbonyl]benzoic Acid 
(LG335) 
3-Propyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronapthylene (2.2 g, 9.5 mmol) and 
chloromethyl terephthalate (2.0g, 10 mmol) were dissolved in dichloroethane (20 mL) 
and  FeCl3 (80 mg, 490 µmol) was added.  The reaction mixture was stirred at 75 °C for 
24 hours.  The reaction was then cooled and MeOH (20 mL) added.  The resulting slurry 
stirred for 7 hours at room temperature, filtered and rinsed with cold MeOH (20 mL) to 
result in 2.1 g (5.5 mmol, 58%) of white crystals [8]. 
The crystals (107 mg, 280 µmol) were stirred in MeOH (2 mL), to which 5N 
KOH (0.5 mL) was added.  This mixture was refluxed for 30 minutes, cooled to room 
temperature and acidified with 20% aqueous HCl (0.5 mL).  The MeOH was evaporated 
and the residue was extracted with EtOAc (2 x 5 mL).  The organic layers were 
combined, dried (MgSO4), and filtered.  The filtrate was treated with hexane (10 mL) and 
reduced in volume to 2 mL.  After standing overnight the resulting crystals were 
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collected to provide 39 mg (103 µmol, 37%) as a white powder [1].  mp 250-252 °C; H1 
NMR (CDCl3) δ 0.88 (t, 3H, -CH2CH2CH3), 1.20 (s, 6H, CH3), 1.32 (s, 6H, CH3), 1.55 
(dt, 2H, -CH2CH2CH3), 1.69 (s, 4H, CH2), 2.65 (t, 2H, -CH2CH2CH3), 7.20 (s, 1H, 
Ar-CH) 7.23 (s, 1H, Ar-CH), 7.89 (d, 2H, Ar-CH), 8.18 (d, 2H, Ar-CH); MS (EI POS) 
m/z mass for C25H30O3: Calc. 378.2189, Found 378.2195; Anal. for C25H30O3: Calc. 
C:79.33, H:7.99, Found C:79.10, H:7.96. 
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CREATION AND DISCOVERY OF LIGAND-RECEPTOR PAIRS FOR SMALL 





 The crystal structure of RXR bound to 9cRA elucidates important hydrophobic 
and polar interactions in the LBD binding pocket [2].  There are 20 hydrophobic and 
polar amino acid side chains within 4.4 Å of the bound 9cRA (Figures 3.1 and 3.2).  RXR 
is a good candidate for creating variants that bind different ligands through site directed 
mutagenesis, because side chain atoms, not main chain atoms, contribute the majority of 
the ligand contacts [2-5].  A library of RXR LBDs with all 20 amino acids at each of the 
20 positions in the ligand-binding pocket screened against multiple compounds could 
potentially produce many new ligand-receptor pairs.   However, the number of possible 
combinations (2020 ≈ 1026) renders saturation mutagenesis impractical for constructing a 
complete library.    
 
 





Figure 3.2  Ligplot [1] depiction of hydrophobic 
interactions between the RXR LBD and 9cRA.  Amino 
acids that are in helices are attached to corresponding coils.  
The other amino acids are in loop regions.  Amino acids 
mutated in this library are boxed.  Coordinates are from 
1FBY.pdb [2]. 
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Codon randomization creates protein libraries with mutations at specific sites [6].  
For a hydrophobic binding pocket, it is justifiable to eliminate many amino acids from 
the list of desirable mutations due to size, charge, or hydrophilicity.  The bases 
comprising each codon can then be adjusted to allow only desirable mutations.  For 
example, Sauer and coworkers [7] allowed only T, A, and G at the first position, T at the 
second position, and C and G at the third position of a codon.  This produces 6 possible 
codons and 5 possible amino acids (L, I, V, F, and M), leading to a manageable library 
size.  A modified version of the Sauer codon randomization method was used to create a 
library of binding pocket variants in RXR.  This library allowed exploration of a large 
and focused quantity of sequence space in a minimal amount of time.   
Chemical complementation is a method which links survival of yeast to the 
presence of a small molecule [8, 9].   Chemical complementation allows testing for 
activation of protein variants by specific ligands using genetic selection.   Here, LG335, a 
synthetic retinoid-like compound (Figure 3.1), was used to test the viability of chemical 
complementation for discovery of ligand-receptor pairs from large libraries.   LG335 was 
previously shown to selectively activate an RXR variant and not activate wild-type RXR 
[4, 10].   Combining chemical complementation with a large library of protein variants 
decreases the time, effort, and resources necessary to find new ligand-receptor pairs.   
Detailed here is my first attempt at large-scale chemical complementation to engineer 







The binding pocket of the RXR LBD is composed of primarily hydrophobic side 
chains plus several positively charged residues that stabilize the negatively charged 
carboxylate group of 9cRA [2].   The target ligand, LG335, contains an analogous 
carboxylate group, so the positively charged residues were left unchanged.   The library 
was designed based on the hypothesis that binding affinity arises from hydrophobic 
contacts and that specificity arises from binding pocket size, shape, hydrogen bonding, 
and electrostatics.   The randomized amino acids were chosen based on their proximity to 
the bound 9cRA as observed in the crystal structure and the results of site directed 
mutagenesis (Figure 3.2) [2, 4].   The electrostatic interactions were held constant while 
the size, shape, and potential hydrogen bonding interactions were varied to find optimum 
contacts for LG335 binding.   A library of RXRs with mutations at six positions was 
created.   At three of the positions (I268, A271, and A272) are four possible amino acids 
(L, V, A, and P) and at the other three positions (I310, F313, and L436) there are eight 
possible amino acids (L, I, V, F, M, S, A, and T).   The combination of six positions and 
number of encoded amino acids allowed testing of the library construction while keeping 
the library size (32,768 amino acid combinations and 2,985,984 codon combinations) 
within reasonable limits.   Proline was included in the library as a negative control.   
Residues 268, 271, and 272 are in the middle of helix 3, which would be disrupted by the 
inclusion of proline.   Therefore, proline residues should appear at these positions only in 
unselected variants and not in the variants that activate in response to ligand.   The 
substitutions at positions 268, 271, and 272 were restricted to small amino acids allowing 
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access to the positively charged residues at this end of the pocket.    
To eliminate contamination of the library with unmutated, wild-type RXR the 
gene was modified to create a non-functional gene, RXR:3Stop.   Forty base pairs were 
deleted at three separate sites producing three stop codons in the coding region to create 
this nonfunctional gene.   The deletions correspond to regions in the RXR gene where 
randomized codons are designed.   This plasmid, pGBDRXR:3Stop, was cotransformed 
into yeast with the library of insert cassettes containing full-length RXR LBD genes with 
randomized codons at positions 268, 271, 272, 310, 313, and 436.   The insert cassettes 
and the plasmid contain homologous regions enabling the yeast to homologously 
recombine the cassette into the plasmid.   Recombination repairs the deletions in the 
RXR:3Stop gene to make full-length genes with mutations at the six specific sites. 
 
Library selection 
To limit the number of variants to be screened, the library was subjected to 
chemical complementation [9] .  Chemical complementation exploits the power of 
genetic selection to make the survival of yeast dependent on the presence of a small 
molecule.  Plasmids created through homologous recombination in PJ69-4A express the 
Gal4 DBD fused with a variant RXR LBD (GBD:RXR).  A plasmid expressing ACTR, a 
nuclear receptor coactivator, fused with the Gal4 activation domain (ACTR:GAD), was 
also transformed into PJ69-4A.  If a ligand causes a variant RXR LBD to associate with 
ACTR, transcription of the ADE2 gene is activated.  Expression of ADE2 permits adenine 
biosynthesis and therefore, yeast survival on media lacking adenine.   










selecting only for the presence of the plasmids pGAD10BAACTR (expressing 
ACTR:GAD and containing a leucine selective marker) and mutant pGBDRXR 
(expressing variant GBD:RXR and containing a tryptophan selective marker).  The 
majority of the yeast cells transformed with the RXR library were plated directly onto SC 
-Ade -Trp -Leu media containing 10 µM LG335, selecting for adenine production in 
response to the compound LG335.  The transformation efficiency of this library into 
yeast strain PJ69-4A was 3.8 × 104 colonies per µg DNA.  This number includes both the 
efficiency of transforming the DNA into the cells and the homologous recombination 
efficiency.  Of the approximately 380,000 transformants, approximately 300 grew on SC 
-Ade -Trp -Leu + 10 µM LG335 selective media. 
 
Library Characterization 
Twenty-one plasmids were rescued from yeast colonies: nine from non-selective 
plates (SC -Trp -Leu) and twelve from selective plates (SC -Ade -Trp -Leu + 10 µM 
LG335).  The relevant portion of plasmid DNA from these colonies was sequenced to 
determine the genotype (Table 3.1).  All nine of the plasmid sequences from the 
non-selective plates contained at least one deletion and are non-functional genes.  Of the 
twelve plasmids that grew on the selective media, all contain full-length RXR LBDs with 
designed mutations.  To evaluate the efficiency of library creation and selection a binary 
approach is taken – either the sequence is or is not a designed sequence. The following 





Table 3.1 Genotypes of variants from unselected and 
selected libraries 
Unselected Library     
   I268 A271 A272 I310 F313 L436 
1 deleted deleted deleted 
2 deleted deleted deleted 
3 GTA(V†) CCT(P) CCT(P)  TCG(S) deleted 
4 deleted deleted deleted 
5 deleted deleted GCG(A) 
6 deleted deleted deleted 
7 deleted deleted deleted 
8 deleted deleted deleted 
9 deleted deleted TTC(F) 
Selected Library     
 I268 A271 A272 I310 F313 L436 
1 GTG(V)  GTG(V) TTG(L) ATG(M) TTG 
2 GTG(V)  GCA GTG(V) TCC(S) TTG 
3 CTA(L) GCT GCA ATG(M) GTG(V) TTG 
4 GCG(A)  GCA TCC(S) GTG(V) TTC(F) 
5 GCT(A) GCT GCA GCC(A) GCG(A) TTC(F) 
6 GCT(A) GCT GTT(V) GCC(A) GCG(A) TTC(F) 
7 CTT(L) GCT GCT GTC(V) ATC(I) TTG 
8 CTG(L) GTG(V) GCG TTG(L) TTG(L) TTG 
9 GTG(V) GTG(V) GCG TTG(L) GTG(V) TTG 
10 GTA(V)  GTG(V) ATG(M) TCC(S) ATG(M) 
11 GCG(A) GCG GCA ATG(M) GCG(A) ACG(T) 
12 GCG(A) GCT GCG TCG(S) GTC(A) TTC(F) 
 
Columns are organized to indicate randomized codons in the same region of the insert 
cassette.  Sequenced codons are indicated followed by the encoded amino acid in 
parentheses.  Where no codon is indicated, the sequence corresponds to the wild-type 
RXR codon.  Where no amino acid is indicated, the codon change did not cause an amino 
acid change.  The presence of an unmutated 3Stop deletion background cassette is 
indicated by “deleted”.   





In this equation, N is the number of sequenced plasmids; k is the number of background 
or designed plasmids; p is the frequency of the occurrence of either background or 
designed plasmid; and P is the measure of certainty.  Applying the equation to the 
libraries, it can be concluded that with 95% certainty that the unselected library is at least 
72% background and the selected library is at least 78% designed sequences. 
 
Variant Characterization in Yeast 
The twelve plasmids rescued from the selective plates were retransformed [11] 
into PJ69-4A to confirm that their phenotype is plasmid linked.  The strain PJ69-4A was 
engineered to contain a Gal4 response element controlling expression of the LacZ gene, 
in addition to the ADE2 gene.  Both selection and screening were used to determine the 
activation level of each variant by 9cRA and LG335.  The selection assay quantifies yeast 
growth occurring through transcriptional activation of the ADE2 gene, while the screen 
quantifies β-galactosidase activity occurring though transcriptional activation of the LacZ 
gene.  The selection assay (Figures 3.3) is ~10-fold more sensitive than the screen (Figure 
3.4) as growth is observed at 10-fold lower ligand concentrations than β-galactosidase 
activity.  However, the selection assay does not quantify activation level (efficacy) as 
well as the screen.  In the selection assay, there is either growth or no growth, whereas 
the screen more accurately quantifies different activation levels at various concentrations 
of ligand (Figures. 3.3 and 3.4).   
Three plasmids were used as controls in the screen and selection assays.  The 
plasmids pGBDRXRα and pGBT9Gal4 were used as positive controls to which the 
activation level of the variants can be compared.  pGBDRXRα expresses the gene for the 
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“wild-type” GBD:RXR, which grows and is activated by 9cRA but not by LG335.  
pGBT9Gal4 expresses the gene for the ligand-independent yeast transcription factor Gal4 
[12], which is constitutively active in the presence or absence of either ligand.  The 
plasmid pGBDRXR:3Stop serves as a negative control.  pGBDRXR:3Stop carries a non-
functional RXR LBD gene; therefore, yeast transformed with this plasmid does not grow 
in the selection assay nor show activity in the screen.  This plasmid provides a measure of 
background noise in both the selection and screen assays. 
Both the selection and screen assays show that ten of the twelve variants are 
selectively activated by LG335.  Results of these assays are shown in Figures 3.3 and 3.4.  
Table 3.2 summarizes the transcriptional activation profiles of all twelve variants in 






Figure 3.3  Selection assay (SC -Ade -Trp -Leu plus ligand medium) for yeast 
growth in the presence of 9cRA (closed circles) and LG335 (open circles) for 




Figure 3.4  Screen assay (SC -Trp -Leu plus ligand  for β-galactosidase activity 
with o-nitrophenyl β-D-galactopyranoside (ONPG) in the presence of 9cRA (closed 
circles) and LG335 (open circles).  Miller units normalize the change in absorbance 
at 405 nm for the change in OD at 630 nm, which reflects the number of cells per 
well.  The 10-12 M point is actually 0 M ligand concentration. 
 
Table 3.2  EC50 and Efficacy in yeast and HEK 293 cells for RXR Variants 
 9cRA LG335 
  Yeast HEK 293 Yeast HEK 293 
  Variant EC50‡ Eff|| EC50 Eff EC50 Eff EC50 Eff 
  (nM) (%) (nM) (%) (nM) (%) (nM) (%) 
  WT 500 100 220 100 >10,000 10 300 10 
  I268A;I310A;F313A;L436F >10,000 0 >10,000 0 220 70 30 50 
  I268V;A272V;I310L;F313M >10,000 10 >1600 30 40 60 1 30 
  I268A;I310S;F313V;L436F >10,000 10   470 60   
  I268A;I310S;F313A;L436F >10,000 0 >10,000 0 430 50 690 20 
  I268V;A272V;I310M;F313S;L436M >10,000 10 >10,000 0 680 30 180 30 
  I268A;A272V;I310A;F313A;L436F >10,000 0   530 30   
  I268L;A271V;I310L;F313L >10,000 0   530 20   
  I268A;I310M;F313A;L436T >10,000 0 >10,000 0 610 10 140 20 
  I268V;A271V;I310L;F313V >10,000 0   650 10   
  I268L;I310V;F313I >10,000 0   >2000 10   
  I268L;I310M;F313V >10,000 20   610 20   
  I268V;I310V;F313S >10,000 0   440 10   
 
‡ EC50, concentration of ligand producing half maximal activity.  Values represent averages of two screen experiments in 
quadruplicate for yeast and in triplicate for HEK 293  
|| Eff, efficacy, maximum increase in activation relative to the increase in activation of wild type with 10 µM 9cRA.  Values represent 




Five variants were chosen for testing in mammalian cell culture for comparison of 
the activation profiles (I268A;I310A;F313A;L436F, I268V;A272V;I310L;F313M, 
I268A;I310S;F313A;L436F, I268V;A272V;I310M;F313S;L436M, and 
I286A;I310M;F313A;L436T).  The genes for these variants were removed from yeast 
expression plasmids and ligated into mammalian expression plasmids (Figure 3.5).   
 
Discussion 
The chemical complementation system presented here focuses on one small 
molecule target ligand and utilizes the power of genetic selection to reveal proteins 
within the library that bind and activate transcription in response to that small molecule.  
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Figure 3.5 Activation of a leuciferase reporter in HEK 293 cells by RXR 
variants in response to 9cRA (A) and LG335 (B).  wt RXR (black circle), 
I268V;A272V;I310L;F313M (red inverted triangle), 
I268A;I310M;F313A;L436T (green square), I268A;I310S;F313A;L436F 
(yellow diamond), I268V;A272V;I310M;F313S;L436M (blue triangle), 
I268A;A310A;F313A;L436F (magenta octagon), and RXR:3Stop (cyan 
circle).  
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from a non-optimized library.  Of the nine plasmids from the unselected library, all nine 
contained sequences that were at least partially background.  Therefore, the majority of 
the library contains at least partial sequence from the non-functional gene (RXR:3Stop) 
used in the recombination process.  Of the 12 plasmids from the selected library, all 
contain designed sequences.  Chemical complementation is very efficient at finding 
functional receptors within a large collection of nonfunctional receptors.   
Importantly, this research demonstrates that ligand-receptor pairs that have 
various activation properties can be created and discovered.  Figures 3.3 and 3.4 depict 
examples of the differing activation profiles, which are summarized in Table 3.2.  Some 
of the variants approach wild-type and Gal4 levels of activation (> 50% Eff., Figure 3.4a 
and c-f), while some are activated only to low (< 25% Eff., Figure 3.4j-l) or moderate 
levels (between 25% and 50% Eff.) (Figure 3.4g-i).  Most of the ligand-receptor pairs act 
like switches (i.e., either on or off) (Figure 3.4h); they are fully activated at one 
concentration, but show no activation at the next lower concentration.  However, some 
act as rheostats (Figure 3.4e); transcription levels can be varied by changing ligand 
concentration over several orders of magnitude.  These variants can be used to titrate 
levels of transcription by varying the concentration of ligand.  The ability to titrate 
transcription levels should be useful in gene therapy to control transcription of 
therapeutic genes and in agriculture to control transcription of pesticidal or other genes. 
Although I268L;I310M;F313V is constitutively active in the selection assay 
(Figure 3.3n) and has high basal activity in the screen assay, both 9cRA and LG335 
increase activity at micromolar concentrations (Figure 3.4n).  This variant may be in an 
intermediate conformation with weakly activated transcription that can be improved by 
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ligand binding.  The high basal activation could also be due to a change in the 
conformation equilibrium with a shift towards the active conformation when ligand is not 
present. 
I268V;I310V;F313S is constitutively active on solid media (data not shown), but 
shows no activation in the screen (0% Eff., Table 3.2, Figure 3.4o) and only grows in the 
liquid media selection after two days (Figure 3.3o).  The basal activation level may be 
below the threshold of detection for the liquid media assays.  However, it is also possible 
that agar, which is not present in the liquid assays, contains some small molecule that 
activates the receptor. 
Activation levels and EC50s correlate in yeast and HEK 293 cells (Figure 3.5 and 
Table 3.2).  For the majority of the variants 9cRA shows little or no activation in yeast or 
mammalian cells.  Variant I268V;A272V;I310L;F313M is activated slightly by 9cRA in 
yeast, but in mammalian cells is activated to the same level as with both 9cRA and 
LG335 (Figures 3.3, 3.4 and 3.5).  With one exception, all variants tested have EC50s 
within 10-fold in yeast and mammalian cells.  However, the EC50s in mammalian cells 
are generally lower than in yeast.  This shift may be due to increased penetration of 
LG335 into mammalian cells versus yeast.   
Subtle differences in binding pocket shape can have a drastic effect on specificity.  
For example, the I268V;A272V;I310L;F313M variant is activated to high levels by 
LG335 (60% Eff., Table 3.2), and is only slightly activated by 10 µM 9cRA in yeast 
(Figure 3.4e), yet the amino acid changes are extremely conservative.  The volume 
difference between phenylalanine and methionine side chains is only ~ 4 Å3 [13] and 
their polarity difference is minimal (hydration potentials of the methionine and 
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phenylalanine side chains are –0.76 kcal mol-1 and –1.48 kcal mol-1, respectively) [14].  
The other mutations redistribute methyl groups within the binding pocket, with a net 
difference of one methyl group (~ 18 Å3) [13] . 
The LG335-I268V;A272V;I310L;F313M ligand-receptor pair also represents a 
25-fold improvement in EC50 over our previous best LG335 receptor, 
Q275C;I310M;F313I (40 nM vs. 1 µM in yeast) [4].  The Q275C;I310M;F313I variant 
was created using site directed mutagenesis. The subtle changes in the 
I268V;A272V;I310L;F313M variant would not have been predicted to produced a better 
ligand receptor pair than the Q275C;I310M;F313I variant.  This conclusion is consistent 
with the observation that nuclear receptors bind ligands through an induced-fit 
mechanism [15].  With current knowledge about protein-ligand interactions it is not 
possible to design ligand-receptor pairs with specific activation profiles.  Libraries and 
chemical complementation are a new way to circumvent this problem and obtain 
functional variants with a variety of activation profiles. 
Molecular modeling was used to generate hypotheses about the structural basis of 
ligand specificity for the variants discovered in the library.  First, mutations to smaller or 
more flexible side chains at positions 310 and 313 are essential to provide space for the 
propyl group of LG335.  All variants activated by LG335 have mutations at these two 
positions.  Second, mutations to amino acids with larger side chains at position 436 
stericly clash with the methyl group at the 9 position of 9cRA.  This interaction may 
prevent helix 12 from closing properly and therefore prevent activation by 9cRA.  The 
only variant significantly activated by 9cRA (I268V;A272V;I310L;F313M) does not 
contain a mutation at position 436.  Third, tight packing in the binding pocket may lead to 
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lower EC50s.  The docking results for I268V;A272V;I310L;F313M with LG335 show 
that the methionine and leucine side chains pack tightly against the propyl group of 
LG335, which may result in tighter binding and consequently a lower EC50. 
In this study, both structural information and functional data from previous site 
directed mutations were utilized for the library design.  In the absence of functional data, 
chemical complementation may be used to test more hypotheses about the function of 
particular residues than would be possible through site directed mutagenesis.  By making 
a library of changes at a single site, additional information could be obtained about the 
importance of side chain size, polarity, and charge over just the traditional mutation to 
alanine that is often used to explore single residue importance.  In the absence of 
structural information, it is possible to make large libraries using error prone PCR or gene 
shuffling.  Chemical complementation could also be used to select active variants from 
these types of libraries. 
Chemical complementation allows high-throughput testing of large libraries.  
Hundreds of thousands of variants can be assayed in one experiment without the spatial 
resolution necessary for traditional screening methods (i.e., no need for one colony per 
well).  Yeast can be spread on solid media and, through the power of genetic selection, 
cells expressing active variants will grow into colonies.  Survivors can then be spatially 
resolved (i.e. transferred to a microplate, one colony per well) for further 
characterization, decreasing the time and effort required to find new ligand-receptor 
pairs. 
Chemical complementation identifies nuclear receptors with a variety of 
responses to a specific ligand.  Nuclear receptors that activate transcription in response to 
 52
targeted molecules and not to endogenous compounds have several additional potential 
applications.  The ability to switch a gene on and off in response to any desired 
compound can be used to build complex metabolic pathways, gene networks, and to 
create conditional knockouts and phenotypes in cell lines and animals.  This ability 
should also be useful in gene therapy and in agriculture to control expression of 
therapeutic or pesticidal genes.  A variety of responses would be useful in engineering 
biosensor array.  An array of receptors with differing activation profiles for a specific 
ligand could provide concentration measurements and increased accuracy of detection.  
The ability to engineer proteins that activate transcription in response to any desired 
compound with a variety of activation profiles will provide a general method of 
engineering enzymes.  Receptors that bind the product of a desired enzymatic reaction 
can be used to select for enzymes that perform this reaction.  The stringency of the assay 
can be adjusted by using ligand-receptor pairs with lower or higher EC50s.  The lack of a 
general system for genetic selection is currently the limiting step for directed evolution of 
enzymes [16, 17].   
 
Materials and Methods 
Ligands 
9-cis retinoic acid (MW=304.44 g/mol) was purchased from ICN Biomedicals. 
LG335 [10] was synthesized [18-22] (Chapter 2). 
 
Expression Plasmids 
pGAD10BAACTR [9, 23] , pGBT9Gal4, pGBDRXRα [8], pCMX-hRXR [24], 
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and pCMX-βGAL [3] have been described. pGBDRXRα was cut with SmaI and NcoI, 
filled in, and blunt-end ligated to eliminate 153 amino acids of the RXR DBD.  A HindIII 
site in the tryptophan selectable marker was silently deleted and the sole remaining 
HindIII site was cut, filled in, and blunt-end ligated to remove the restriction site.  Unique 
HindIII and SacI sites were inserted into the RXR LBD gene and MfeI and EcoRI sites 
were removed from the plasmid using QuikChange Site-Directed Mutagenesis 
(Stratagene, La Jolla, CA) to create pGBDRXRαL-SH-ME.  pCMX-hRXR mutants were 
cloned from pGBDRXR vectors using SalI and PstI restriction enzymes and ligated into 
similarly cut pCMX-hRXR vectors. pLuc_CRBPII_MCS was made by site-directed 
mutagenesis from pLucMCS (Stratagene, USA).  Site-directed primers were designed to 
incorporate a CRBPII response element in the multiple cloning site (MCS), controlling 




The zero background plasmid, pGBDRXR:3Stop, was constructed using 
QuikChange Site-Directed Mutagenesis with pGBDRXRαL-SH-ME as the template and 
the 3Stop insert cassette (described below) as primers. 
The 3Stop insert cassette was synthesized using PCR from eight oligonucleotides 
(Figure 3.6).   All PCRs were done using 2.5 U Pfu Polymerase (Stratagene, LaJolla, 
CA), 1x Pfu buffer, 0.8 mM dNTPs, 50 ng of pGBDRXRαL-SH-ME as a template, 125 
ng of primers and sterile water to make 50 µL. First, four small cassettes were 
synthesized in reactions containing the following primers:  Cassette 1, F 
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(5’-CGGAATTTCC CATGGGC-3’), BPf (5’-CTCGCCGAAC GACCCGGTCA 
CCGCATGCCA CTAGTGG-3’), and BPr (5’-CCGCTTGGCC CACTCCACTA 
GTGGCATGCG GTGACC-3’); Cassette 2, BPf, BPr, SEf (5’-CGGGCAGGCT 
GGAATGAGCT CCTCGACGGA ATTCTCC-3’), and SEr (5’-CAGCCCGGTG 
GCCAGGAGAA TTCCGTCGAG GAGCTC-3’); Cassette 3, SEf, SEr, AMf 
(5’-CTCTGCGCTC CATCGGGCTT AAGTGCCCAC CAATTGACAC-3’), and AMr 
(5’-CTCCAGCATC TCCATAAGGA AGGTGTCAAT TGGTGGGCAC TTAAGC-3’); 
Cassette 4, AMf, AMr, and R (5’-CAAAGGATGG GCCGCAG-3’).  The cassettes were 
cleaned with either the DNA Clean and Concentrator-5 (Zymo Research, Orange, CA) or 
the Zymoclean Gel DNA Recovery Kit (Zymo Research, Orange, CA) depending on 
product purity.  The four cassettes were used to make the final 3Stop insert cassette in a 
PCR that contained each cassette, primers F and R, dNTPs, Pfu Polymerase, and sterile 
water to a final volume of 50 µL.  The 3Stop cassette was cleaned using the Zymoclean 




Figure 3.6  Construction of pGBDRXR:3 stop. 
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Insert Cassette Library Construction 
The library of insert cassettes with randomized codons was constructed in a 
similar manner as above.  The four cassettes (FBP, BPSE, SEAM and AMR) were made 
in the following ways (Figure 3.7). 
For the FBP cassette, oligos BP1 (5’-GGCAAACATG GGGCTGAACC 
CCAGCTCGCC GAACGACCCG GTCACC-3’), BP2 (5’-GCCCACTCCA 
CTAGTGTGAA AAGCTGTTTG TC (A, C, or T)(A or G)(C or G)(A, C, or T)(A or 
G)(C or G)TT GGCA(A, C, or T)(A or G)(C or G)GTT GGTGACCGGG 
TCGTTCG-3’), BP3 (5’-CTTTTCACAC TAGTGGAGTG GGCCAAGCGG 
ATCCCACACT TCTCAGAG-3’), and BP4 (5’-GGGGCAGCTC TGAGAAGTGT 
GGGATCCG-3’) were mixed with TE containing 100 mM NaCl to bring the total 
volume to 50 µL.  The mixture was heated to 95 °C for 1 minute, then slowly cooled to 
10 °C.  The annealed mixture was combined with EcoPol Buffer, dNTPs, ATP, Klenow 
(NEB, Beverly, MA), T4 DNA ligase (NEB, Beverly, MA) and sterile water to 200 µL, 
and kept at 25°C for 45 min before heat inactivation at 75°C for 20 minutes.  The product 
was cleaned with DNA Clean and Concentrator-5 to make the BP cassette.  Next, BP 
cassette was combined with Pfu Buffer, pGBDRXR:3Stop, oligo F, dNTPs, Pfu 
polymerase, and sterile water to make 50 µL for a PCR.  The final FBP product (300bp) 
was purified using the Zymoclean Gel DNA Recovery Kit. 
  BPSE was made in two consecutive PCRs.  First, SE1 (5’-GCAGGCTGGA 
ATGAGCTCCT C(A, G, or T)(C or T)(G or C)GCCTCC (A, G, or T)(C or T)(G or 
C)TCCCACC GCTCCATC-3’) and SE2 (5’-CCGGTGGCCA GGAGAATTCC 
GTCCTTCACG GCGATGGAGC GGTGGG-3’) were combined with Pfu buffer, 
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dNTPs, Pfu polymerase, and sterile water to make 50 µL.  After 5 PCR cycles, 
pGBDRXR:3Stop and BP were added to the reaction and the PCR was continued for 30 
cycles.  The product (240 bp) was purified using the Zymoclean Gel DNA Recovery Kit. 
SEAM was constructed in a similar way to BPSE.  SE1 and SE2 were mixed with 
Pfu Buffer, dNTPs, Pfu polymerase, and sterile water to 25 µL.  Simultaneously, AM1 
(5’-GGCTCTGCGC TCCATCGGGC TTAAGTGCCT GGAACAT(A, G, or T)(C or 
T)(G or C) TTSCTTCTTC AAGCTCATCG GGG-3’) and AM2 (5’-GCATCTCAAT 
AAGGAAGGTG TCAATTGTGT GTCCCCGATG AGCTTGAAGA A-3’) were 
combined with Pfu Buffer, dNTPs, Pfu polymerase, and sterile water to 25 µL.  After 5 
cycles, these two reactions were mixed and pGBDRXR:3Stop was added. The PCR was 
continued for 30 cycles.  The PCR product (460 bp) was purified using the Zymoclean 
Gel DNA Recovery Kit.  
The AMR cassette was made similarly to FBP.   AM1 and AM2 were mixed with 
TE containing 100 mM NaCl to make 50 µL, heated to 95°C for 1 minute, then slowly 
cooled to 10°C.  The annealed mixture was combined with EcoPol Buffer, dNTPs, 
Klenow, and sterile water to 200 µL, and kept at 25°C for 45 min before heat inactivation 
at 75°C for 20 minutes.  The product (AM) was precipitated with isopropanol.  Next, AM 
and R were combined with Pfu buffer, pGBDRXR:3Stop, dNTPs, Pfu Polymerase, and 
sterile water to make 50 µL for a PCR.  The product (140 bp) was purified using the 
Zymoclean Gel DNA Recovery Kit.   
The four cassettes (FBP, BPSE, SEAM, and AMR) were combined in a PCR to 
make the library of randomized insert cassettes (6mutIC).  The library was cleaned using 





Figure 3.7  Construction of insert cassette library.  Asterisks indicate location 
of randomized codons. 
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Yeast selection plates and transformation 
Synthetic complete (SC) media and plates were made as previously described [8].  
Selective plates were made without tryptophan (-Trp) and leucine (-Leu) or without 
adenine (-Ade), tryptophan (-Trp) and leucine (-Leu).  Ligands were added to the media 
after cooling to 50 °C. 
 The randomized cassette library was homologously recombined into the 
pGBDRXR:3Stop plasmid using the following method.  pGBDRXR:3Stop was first 
digested with BssHII and EagI (NEB, Beverly, MA), and then treated with calf intestinal 
phosphatase (NEB, Beverly, MA), to make a vector cassette.  Vector cassette (1 µg) and 
6mutIC (9 µg) were transformed according to Geitz’s transformation protocol [11] on a 
10X scale into the PJ69-4A yeast strain, which had previously been transformed with a 
plasmid (pGAD10BAACTR) [9] expressing the nuclear receptor coactivator ACTR fused 
to the yeast Gal4 activation domain.  Homologous regions between the vector cassette 
and the insert cassette allow the yeast to homologously recombine the insert cassette with 
the vector cassette forming a circular plasmid with a complete RXR LBD gene.  The 
transformation mixture (1 mL) was spread on each of 10 large plates of SC -Ade -Trp 
-Leu media containing 10 µM LG335.  The transformation mixture (2 and 20 µL) was 
also spread on SC -Trp -Leu media.  These plates were grown for 4 days at 30 °C. 
 
Genotype Determination 
Plasmids were rescued using either the Powers method 
(www.fhcrc.org/labs/gottschling/yeast/yplas.html) or the Zymoprep Kit (Zymo Research, 
Orange, CA). The plasmids were then transformed into Z-competent (Zymo Research, 
 60
Orange, CA) XL1-Blue cells (Stratagene, La Jolla, CA). The QIAprep Spin Miniprep Kit 
(Qiagen, Valencia, CA) was used to purify the DNA from the transformants. These 




The rescued plasmids were transformed [11] into PJ69-4A containing the 
pGAD10BAACTR plasmid and plated on SC -Trp -Leu media. These plates were grown 
for 2 days at 30 °C. 
 Colonies were streaked onto the following media: SC, SC -Trp -Leu, SC -Ade 
-Trp -Leu, SC -Ade -Trp -Leu plus increasing concentration of LG335 or 9cRA from 1 
nM to 10 µM. 
 
Liquid Media  
The method used for quantitation in the paper was modified from a method developed by 
Miller [25]. Briefly, SC -Trp -Leu media was inoculated with PJ69-4a containing the 
pGBDRXR plasmid of choice and the pGAD10BA:ACTR plasmid and grown overnight 
at 30 °C with shaking.  The cultures were centrifuged at 5000 rpm for 5 minutes and 
washed twice with sterile water.  The cultures were then used to inoculate 100 µL of 
either SC -Trp -Leu (screen) or SC -Ade -Trp -Leu (selection) media in 96-well plates.  
The OD630 was taken with an OpsysMR plate reader (Dynex Technologies, Chantilly, 
VA).  These were grown for 1 to 2 days at 30 °C with moderate shaking.  For selection 
experiments, the OD630 was recorded after 1 and 2 days.  For screens, the OD630 was 
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taken after 24 hours.  The yeast was pelleted and the supernatant was removed.  The cells 
were lysed with yeast lytic enzyme and Triton X-100.  After lysis, the cell debris was 
pelleted by centrifugation and the supernatant moved to new 96-well plates.  ONPG was 
added to the wells and the OD405 was recorded.  The plates were incubated at 37 °C for 
30 to 60 minutes.  The reaction was quenched with sodium carbonate and the OD405 was 
recorded again.  Miller units were calculated using Equation 4.2 where v is the culture 
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Mammalian Luciferase Assay 
HEK 293 cells were cultured in DMEM supplemented with 10% calf bovine 
serum. Twenty-four hours before transfection, 8×104 cells per well were plated in a 48 
well plate.  pCMX-hRXR mutants (20ng) were cotransfected with pLucCRBPII (40ng) 
and pCMX-βGal (40ng) using lipofectamine cationic lipid according to the protocol  
recommended by the manufacturer (Gibco BRL/Life Technologies) . After 10 h of 
transfection, dilutions of ligands 9cRA and LG335 were prepared in super-stripped media 
and added to the plate in triplicate. Cells were harvested after 36 h and assayed for 
luciferase and β−galactosidase activity.  
 
Molecular Modeling   
Docking of LG335 in to modified binding pockets was done using the InsightII 
module Affinity.  The wild type RXR with 9cRA crystal structure [2] was modified 
using the Biopolymer module residue replace tool to make mutations in the binding 
(3.2) 
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pocket that corresponded to the mutations in variants I268;I130A;F313A;L436F, 
I268V;A272V;I310L;F313M, and I268A;I310S;F313A;L436F.  The ligand was placed in 
the binding pocket by superimposing the carboxylate carbon and two carbons in the 
tetrahydronapthalene ring of LG335 onto corresponding carbons of 9cRA in the crystal 
structure.  A Monte Carlo simulation was performed first, followed by Simulated 
Annealing of the best docked conformations.  See chapter 1 for a more complete 
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VARIABLE STRINGENCY CHEMICAL COMPLEMENTATION 




 Chemical complementation is a powerful method to find receptors that are 
activated by a specific small molecule.  However, when large libraries (>100,000 
variants) of receptors are expressed in yeast, the number of hits (receptors activated by 
the desired ligand) may be too numerous to practically analyze.  Many of the variants 
may only slightly activate transcription or have high EC50s (in the µM range).  It is 
desirable to have a versatile selection method with which the receptors that have high 
efficacy and low EC50s can be identified.  To this end, a chemical complementation 
selection method with variable stringency was developed.  With variable stringency 
genetic selection, chemical complementation can identify not only receptors that are 
activated by the targeted small molecule, but also those that have the desired property of 
high activation levels.  The HIS3 gene encodes the enzyme imidazole glycerolphosphate 
dehydratase, which is inhibited by 3-amino-1,2,4-triazole (3AT).  Using the HIS3 gene as 
a selective marker, the concentration of 3AT can be varied to adjust the stringency of 
chemical complementation.  The concentration of ligand can also be varied to identify 
receptors with low EC50s.  Hits with desired properties originally identified through 
chemical complementation on solid medium can be characterized using variable 




 A library was designed based on the results of the previous library [2] (Chapter 3) 
with mutations at amino acid positions 268, 271, 272, 310, 313, and 436.  All six 
positions are randomized to L, I, V, F, M, A, S, and T creating a new library with 
262,144 amino acid combinations (2,985,984 codon combinations).  As with the previous 
library, the plasmid pGBDRXR:3Stop encoding a non-functional RXR gene is used to 
eliminate wild-type background. 
 The library of full-length RXR LBD genes with randomized codons at positions 
268, 271, 272, 310, and 313 and doubly cut pGBDRXR:3Stop vector were co-
transformed into yeast.  The synthetic library cassettes and the cut vector contain 
homologous regions enabling the yeast to insert the cassette into the vector by 
homologous recombination, thereby creating full length RXR LBD genes with mutations 
at the desired positions.  A 30x transformation with 3 µg vector and 27 µg library cassette 
was performed using the Gietz method [3].  
 
Library Selection 
Chemical complementation was used to select RXR variants that are activated by 
LG335.  After transformation, the yeast were plated onto medium (SC -Trp -Leu) 
selecting for two plasmids: pGBDRXR and pGAD10BAACTR.  The transformation / 
recombination efficiency of this library into the yeast strain PJ69-4A was 1.4 × 105 
colonies per µg of vector with a total of ~450,000 transformants.  These plates were 
replica plated onto SC -Ade -Trp -Leu medium plus 10 µM LG335.  Approximately 1000 
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colonies grew on the selective plates.  These colonies were picked and stored in 96-well 
plates at -80 °C in SC -Trp -Leu medium with 15% glycerol. 
 
Variable Stringency Selection 
 The goal for developing a variable stringency selection method is to raise the 
thranscription activation threshold required for yeast growth (Figure 4.1).  The amount of 
activation necessary to allow yeast growth using the adenine selective marker with 
chemical complementation is approximately 10% or less of wild type activation with 
9cRA based on the activation and growth profiles of previously characterized variants 
(Chapter 3).  The variants with maximum activation levels of ~10% are not very useful 
for practical applications of ligand receptor pairs.  To remove these low efficacy variants, 
a selection system with a high activation threshold for growth is desirable.   
The PJ69-4A yeast strain has a HIS3 selective marker under the control of a Gal4 
response element.  The HIS3 gene encodes imidazole glycerolphosphate dehydratase, an 
essential enzyme in the histidine biosynthetic pathway.  This enzyme is inhibited by 3AT.  
By adjusting the concentration of 3AT in SC -His -Trp -Leu medium the stringency of 
 
Figure 4.1 Schematic depicting 
increasing the activation threshold for 
chemical complementation.  
Chemical complementation with 
adenine selection has a low activation 
threshold that allows growth (red 
line).  A higher activation threshold 
(green line) is desired to increase the 
stringency of genetic selection, 
selecting against low efficacy RXR 
variants. 
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the selection can be tuned. 
 Three concentrations of 3AT (20, 40, and 100 mM) were tested to determine the 
oeffective concentration for selecting against transformants with low efficacy receptors 
(data not shown).  Using 100 mM 3AT in SC -His -Trp -Leu liquid medium plus 10 µM 
LG335, of the 1000 transformants tested, 35 transformants (deemed a reasonable number 
for further analysis) grew to a ∆OD630 greater than 0.300.  Plates grown with 20 and 40 
mM 3AT had 10 and 2 fold more transformants growing to a ∆OD630 greater than 0.300, 
respectively. 
 The 35 transformants were then assayed for low EC50s.  Each transformant was 
grown in SC -His -Trp -Leu medium plus 10 µM or 10 nM LG335 and 100 mM 3AT.  
SC -His -Trp -Leu plus 100 mM 3AT, and SC -Trp -Leu medium were used as controls.  
Of the 35 transformants, eight grew with 10 nM LG335 (Figure 4.2).  The plasmids in 
these transformants were rescued and sequenced.  For two of the plasmids (2.B1 and 
8.D7) complete sequencing was not obtainable for unknown reasons.  The plasmids for 
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 Ten plasmids from the naïve library were also sequenced.  Since this library was 
constructed in the same manner as the library created in Chapter 3, it was expected to 
contain mostly non-functional background.  Of the ten plasmids sequenced from the 
naïve library, one plasmid contained the designed sequence, four plasmids were 
pGBDRXR:3Stop, one plasmid had one deleted cassette, and four plasmids had two 
deleted cassettes.  All of the plasmids from the selected library that could be completely 
sequenced contained the designed library.  With 95% certainty, the naïve library is at 
least 62% background and the selected library is at least 61% designed sequences as 
calculated using a binomial distribution (Chapter 3).  At most, this library covers 6% of 
the total possible DNA sequences.  
 
Variant Characterization 
 Both chemical complementation selection (adenine selection) and screen (β-
galactosidase activity) assays were performed to characterize the six variants after 
retransformation (Figures 4.3 and 4.4 and Table 4.1). Wild-type RXR and Gal4, a ligand 
independent yeast transcription factor, were used as controls.  Five of the six variants are 
selectively activated by 9cRA.  The sixth variant (I310L;F313M;L436M) is activated by 
a lower concentration and to a higher level with LG335 versus 9cRA.  Table 4.1 
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Figure 4.3  Selection assay ( SC -Ade -Trp -Leu plus ligand medium) for yeast 
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Figure 4.4 Screen assay (SC -Trp -Leu plus ligand medium) for β-
galactosidase activity with o-nitrophenyl β-D-galactopyranoside (ONPG) in the 
presence of 9cRA (black) and LG335 (red).  Miller units normalize the change 
in absorbance at 405 nm for the change in optical density at 630 nm, which 




  Using the Insight II docking module Affinity (Accelrys), LG335 was docked into 
each of the six RXR variants discovered using variable stringency selection as well as 
twelve RXR variants previously discovered (Chapter 3) [2].  The variants were created in 
silico starting with the RXR-9cRA crystal structure [4] and using the Biopolymer 
module’s residue replacement feature.  The side chains (past the β-carbon) of the 
replaced residues were energy minimized.  Docking was accomplished using Metropolis 





Table 4.1 EC50 and Efficacy for RXR Variants    
  9cRA LG335 
Variant Variant EC50ξ Eff£ EC50 Eff 
 Code (nM) (%) (nM) (%) 
 WT  100 100 >10,000 10 
 I310L;F313M;L436M 2.D5 600 90 20 190 
 I268V;A271S;I310V;F313V;L436V 10A.B7 >10,000 0 200 80 
 I268A;A271S;A272S;I310M;F313L 10A.E8 >10,000 0 100 100 
 I268A;A271S;I310V;F313V;L436V 10A.C7 >10,000 0 300 140 
 I268M;I310V;F313L;L436A 10A.E6 >10,000 0 60 70 
 A271S;A272T;I310S;F313L;L436A 1.E2 >10,000 0 200 40 
 
ξ EC50, concentration of ligand producing half maximal activity.  Values represent 
averages of three screen experiments in quadruplicate. 
£ Eff, efficacy, maximum increase in activation relative to the increase in activation of 




Variable Stringency Selection 
 Under normal conditions, chemical complementation using the HIS3 gene as a 
selective marker is less stringent that ADE2 selection [5].  3AT is an inhibitor for the 
enzyme imidazole glycerolphosphate dehydratase encoded by the HIS3 gene.  Adjusting 
the concentration of 3AT in the selection assay alters the stringency of selection; as the 
concentration of 3AT increased, the number of transformants that survived the selection 
decreased.  To survive selection with high concentrations of 3AT, a large quantity of 
enzyme must be present.  The amount of enzyme in a cell is related to the transcriptional 
activation of that particular gene.  Therefore, for a transformant to survive selection with 
high concentrations of 3AT in chemical complementation, the receptor must be able to 
activate transcription effectively enough for the transformant to produce enough 
imidazole glycerolphosphate dehydratase to overcome inhibition by 3AT. 
 A variable stringency selection is desirable when a great number of transformants 
survive the initial round of chemical complementation.  In this case, 1000 transformants 
grew on solid medium in response to LG335.  It was not practical to screen all 1000 
transformants for activity to discover the variants with the highest activation and lowest 
EC50s.  Using a more stringent chemical complementation allowed selection of the best 
six variants in two high-throughput experiments.  The variability of this selection system 
allows the user to adjust the stringency of the selection to meet the needs of the 




 LG335 was docked into each of 18 variants that are activated by LG335.  The 
goal was to compare the energies and structures of the docked complexes to the EC50 and 
efficacy values for each of the 18 variants to create hypotheses about binding and 
activation properties to explain the activities of these variants and for use in designing 
future libraries.  Each calculation produced between two and five docked structures for 
each variant.  The force field used for this docking (CVFF) is similar to typical docking 
force fields in that there are no terms to calculate changes in desolvation energy or loss of 
conformational entropy for the ligand.  Since the ligand is constant for this set of docking 
calculations, these values are identical for each set of calculations and therefore it is 
justifiable to directly compare the results.  However, we must assume that the solvation 
and conformational entropy of the protein does not change significantly among variants. 
 A problem that was not anticipated arose during the evaluation of the docking 
results.  Because the protein is “mutated”, the energy of the protein changes based on the 
mutations made.  Although this energy change is small compared to the overall energy of 
the total protein, enough uncertainty is introduced between variants that when the 
interaction energy between the ligand and the protein is calculated, the uncertainty is 
greater than the final interaction energy values.  Therefore, although the energies of the 
docked structures of the same variant can be compared to determine the best position of 
the ligand, it is not appropriate to compare the energies of different variants.  To 
overcome this problem free energy perturbation (FEP) could be used to transform wild-
type RXR into each of the variants followed by docking calculations.  The FEP 
calculations would give an energy difference between wild-type RXR and each variant 
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that could be used to normalize the docking calculation energies.  This solution exceeds 
the scope of this study. 
The docked structure with the lowest total energy correlates to the expected 
docked structure in 17 of the 18 variants (Figure 4.5).  These docked structures have the 
carboxylate of LG335 in a similar position to the carboxylate of 9cRA in the crystal 
structure.  In this position, the carboxylate is within 2.5 Å of the amide backbone 
hydrogen of A327 and the guanidinium group of R316 (Figure 4.5 A and B).  Half of the 
docked structures are also within 2.5 Å of the side chain amide of Q275, which in the 
crystal structure is facing away from the binding pocket and toward the solution (Figure 
4.5 C).  Because of the position of Q275, it is reasonable that the side chain of this 
residue could rotate inward and provide additional stability through a hydrogen bond to 
the carboxylate of the bound LG335. 
 The docked structure with the lowest total energy for 
A271S;A272T;I310S;F313L;L436A did not correlate with the expected docked structure 
(Figure 4.5C).  In the structure with the lowest total energy, the carboxylate is within 2.5 
Å of the hydroxide hydrogen of serines 314 and 317 and the n-propyl group is directed 
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Figure 4.5  (A)Wild type RXR crystal structure with 9cRA and LG335 docked into (B) I268V;A272V;I310L;F313M, (C) 




Table 4.2  LG335 activated RXR variants 





Eff.   
(%) 
1 b    L M M 4 20 190 
2 a V  V L M  -12 40 60 
3 b M   V L A 80 60 70 
4 b A S S M L  48 100 100 
5 b V S  V V V 71 200 80 
6 b  S T S L A 78 200 40 
7 a A   A A F 165 220 70 
8 b A S  V V V 109 300 140 
9 a A   S A F 157 430 50 
10 a V   V S  92 440 10 
11 a A   S V F 120 470 60 
12 a L V  L L  -25 530 20 
13 a A  V A A F 127 530 30 
14 a L   M V  26 610 20 
15 a A   M A T 145 610 10 
16 a V V  L V  8 650 10 
17 a V  V M S M 31 680 30 
18 a L   V I  28 2000 10 
 
Ŧ Library source for each variant.  a indicates library created in Chapter 3 and b 
indicates library created in Chapter 4. 
† The difference in volume of the binding pocket in the variant versus the wtRXR 
binding pocket, calculated by subtracting the volume of the amino acid side chain in the 
variant from the volume of the with type side chain [1].  Values greater than 0 indicate 
a larger binding pocket. 
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Variant Analysis 
  Table 4.2 contains a summary of the variants activated by LG335.  Several trends 
are observed upon analysis.  First, every variant has mutations at positions 310 and 313 
indicating that the residues at these positions in wild-type  RXR, isoleucine and 
phenylalanine, must interact poorly with LG335.  Based on the docking results we 
hypothesize that the propyl group of LG335 sterically clashes with the wild-type side 
chains at these positions. 
A second observation invloves positions 271 and 272.  For the first library 
(Chapter 3), mutations at these two positions were restricted to L, V, A, or P.  For the 
current library, the possibilities were expanded to include L, I, V, F, M, A, S, or T.   
However, other than the wild type amino acid alanine, the only residues observed at these 
two positions are V, S, and T.  We hypothesized that large side chains at 271 or 272 
would disrupt access to the positively charged end of the binding pocket and therefore 
would not lead to functional receptors.  Based on the results of these two libraries, we 
find that this hypothesis is most likely correct. 
Finally, of the 18 variants, 13 contain an additional polar amino acid in the 
binding pocket.  The threonine, serine, and methionine residues were included in the 
library to add possible hydrogen bonding sites.   However, these residues do not seem to 
be participating in hydrogen bonding.  It is interesting to note that although these amino 
acids are not participating in hydrogen bonds, the best ligand-receptor pairs would not 
have been found if these amino acids had not been included in the library.  These residues 
may be decreasing the hydrophobicity of the binding pocket, thereby making the binding 
pocket environment more favorable for the less hydrophobic ligand LG335 and less 
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favorable for the more hydrophobic ligand 9cRA. 
Table 4.2 contains the changes in binding pocket volume, efficacy, and EC50 for 
each variant activated by LG335.  No statistical correlation is evident between binding 
pocket size change and either EC50 or efficacy (Figure 4.6) 
 
Materials and Methods 
Compounds 
9cRA (molecular weight of 300.4 g/mol) was purchased from BIOMOL 
(Plymouth Meeting, PA).  LG335 [6] was synthesized as described [2] (Chapter 2).  3-
Amino-1,2,4-triazole (3-AT) was purchased from Sigma (St. Louis, MO). 
 
Expression Plasmids 
pGBDRXR:3Stop [2], pGAD10BAACTR [5, 7], pGBT9Gal4, and  
pGBDRXRαL-SH-ME [8] have been described. 
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Figure 4.6  No correlation is found between binding pocket volume and (A) 
EC50 or (B) efficacy. 
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Randomized Cassette Library Construction 
The insert cassette 6mutIC was made as previously described [2] (Chapter 3), but 
oligo BPrev2cor (5’-GCCCACTCCACTAGTGTGAAAAGCTGTTTGTC (G or C) (A or 
G) (A, C, or T) (G or C) (A or G) (A, C, or T) GTTGGTGACCGGGTCGTTCG-3’) was 
used instead of BP2.  The randomized codons code for L, I, V (2), F, M, A (2), S (2), and 
T (2).  
 
Transformation 
The randomized cassette library was homologously recombined into the 
pGBDRXRa:3Stop plasmid using to following method.  pGBDRXRα:3Stop was first 
digested with BssHII and EagI (NEB), followed by digestion with calf intestinal 
phosphatase (NEB), to make a vector cassette.  3 µg of this vector cassette and 27 µg of 
6mutIC were transformed according to Geitz’s Two Hybrid System TRAFO Protocol [3] 
on a 30X scale into the PJ69-4A yeast strain, which had previously been transformed 
with a plasmid expressing the coactivator ACTR.  2.5 mL of the transformation mixture 
was spread on each of twelve large, square (24 cm  ×  24 cm) plates of SC -Trp-Leu 
medium.  These plates were grown for 4 days at 30 °C. 
 These twelve plates were then replica plated onto SC -Ade -Trp -Leu and SC 
-Ade -Trp -Leu plus 10 µM LG335.  The plates were grown at 30 °C for 3 days.  
Colonies that grew on the plates with LG335, but not on plates without ligand were 
picked by hand and inoculated into wells on 96-well plates containing SC -Trp -Leu 
liquid medium.  The 96-well plates were grown at 30 °C with shaking at 150 rpm 
overnight.  To each well, 50 µL of 75% glycerol in water was added and mixed.  The 
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plates were frozen at -80 °C for storage.  
 
Variable Stringency Selection 
The 96-well plates were replicated into SC -Trp -Leu medium using a 96-pin plate 
replicator (Boekel).  These plates were grown at 30 °C with shaking.  After 48 hours of 
growth, these plates were then replicated into 96-well plates containing SC -Trp -Leu, SC 
-His -Trp -Leu + 3AT (20, 40 or 100 mM) and SC -His -Trp -Leu + 3AT (20, 40 or 100 
mM) + 10 µM LG335.  These plates were grown at 30 °C with shaking for 24 hours.  
Each well was evaluated for growth by collecting the optical density at 630 nm with an 
OpsysMR plate reader (Dynex Technologies, Chantilly, VA).  Yeast from wells that had a 
change in optical density greater than 0.300 were streaked onto solid SC -Trp -Leu 
medium and grown for 3 days at 30 °C.   
 
Low EC50 Selection 
The colonies that passed the increased stringency selection with 100 mM 3AT 
were picked and grown overnight at 30 °C with shaking (300 rpm).  These cultures were 
washed twice with sterile water and diluted to 1.5 × 107 cells/mL.  96-well plates were 
filled with 80 µL per well of SC -Trp -Leu, SC -His -Trp –Leu + 100 mM 3-AT, SC -His 
-Trp –Leu + 100 mM 3-AT + 10 µM LG335, and SC -His -Trp –Leu + 100 mM 3-AT + 
10 nM LG335.  To three wells per plate, 20 µL of each diluted yeast culture was added.  
These plates were grown for two days at 30 °C with shaking (150 rpm).  Growth was 
monitored at 24 and 48 hours by recording the OD at 630 nm.     
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Liquid Quantification Assay 
The method used for quantification was modified from a method developed by 
Miller [9].  Briefly, SC -Trp -Leu medium was inoculated with PJ69-4A containing the 
pGBDRXR plasmid of choice and the pGAD10BAACTR plasmid and grown overnight 
at 30 °C with shaking.  The cultures were centrifuged for 15 minutes and washed twice 
with sterile water.  The cultures were then used to inoculate 80 µL of either SC -Trp -Leu 
(screen) or SC -Ade -Trp -Leu (selection) medium with increasing concentrations of 
ligand in 96-well plates.  The OD630 was taken with an OpsysMR plate reader (Dynex 
Technologies, Chantilly, VA).  These were grown for 1 to 2 days at 30 °C with moderate 
shaking.  For selection experiments, the OD630 was recorded after 1 and 2 days.  For 
screens, the OD630 was taken after 24 hours.  The yeast was pelleted and the supernatant 
was removed.  The cells were lysed with 10 mg mL-1 yeast lytic enzyme (MP 
Biomedicals) and 0.1% Triton X-100 (Sigma).  After lysis, the cell debris was pelleted by 
centrifugation and the supernatant moved to new 96-well plates.  ONPG was added to the 
wells and the OD405 was recorded.  The plates were incubated at 37 °C for 30 to 60 
minutes.  The reaction was quenched with sodium carbonate and the OD405 was recorded 
















Plasmids were rescued using the Zymoprep Kit (Zymo Research, Orange, CA).  
The plasmids were then transformed into Z-competent (Zymo Research, Orange, CA) 
XL1-Blue cells (Stratagene, La Jolla, CA).  The QIAprep Spin Miniprep Kit (Qiagen, 
Valencia, CA) was used to purify the DNA from the transformants.  Plasmids were 
confirmed through sequencing. 
 
Docking 
 The A chain and the associated crystallographic waters of the RXR-9cRA crystal 
structure [4] was used for this docking.  A 5 Å layer of explicit water was added to the 
exterior of the protein.  All water molecules were removed from the binding pocket.  
Variants were created using the residue replacement tool in the Biopolymer module of 
Insight II (Accelrys).  After replacement, the side chains (not including the α- or β-
carbons) were energy minimized to a maximum derivative of 0.001 using the steepest 
descents and conjugate gradient methods.   
LG335 was superimposed upon the crystallographic 9cRA for use as the starting 
structure.  Affinity (Accelrys) was used for docking LG335 into each of 18 variants. 
Metropolis Monte Carlo simulation was first implemented to find alternative docked 
structures.  The initial temperature of 500 K was used for the metropolis acceptance filter.  
If no structure was found, the temperature was increased to 700 K and 1000 K in 
successive trials.  The program was set to find twenty structures and accept the best ten, 
however, the most structures found was five. 
Each of the accepted structures was further optimized using simulated annealing.  
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Simulated annealing was preformed from 500 K to 300 K in fifty 100 fs intervals.  The 
resulting structures were analyzed for total energy of the system, energy of the ligand, 
energy of the protein, and interaction energy between the ligand and protein using a 
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 Discovering a variety of receptors that are responsive to different small molecules 
is important for the development of biosensors, gene therapy, and enzyme engineering.  
For biosensors, arrays of receptors could be used to detect explosives, biotoxins, and 
chemical weapons.  The pattern of activation on the array could precisely identify the 
agent detected.  For gene therapy, receptors that activate transcription in response to 
different drugs could be used to control expression of multiple genes.  The specific dose 
of each drug could be adjusted based on the patient's needs.  Finally, for enzyme 
engineering, receptors that bind the desired product of a reaction, but not the precursors, 
could aid in identification of enzymes with novel catalytic abilities.  
 The ultimate goal of this research is to be able to find receptors for arbitrary 
ligands.  To this end, an approach combining computational screening, library design, 
and chemical complementation was used to identify receptors for a specific compound, γ-
oxo-1-pyrenebutyric acid (OPBA), that is not known to be bound by RXR or any other 
nuclear receptor.  




High Throughput Docking 
 To identify potential ligands, the software program FlexX (BioSolveIT) [2] was 
used to screen large databases for compounds that would fit in the binding pocket of 
RXR. FlexX was designed to automatically dock small molecules into proteins in a high-
throughput manner (see Chapter 1 for a full description). 
The Developmental Therapeutics Program (DTP) database from the National 
Cancer Institute was the first target library of potential ligands.  This database contains 
three-dimensional coordinates for 127,000 compounds, most of which are freely available 
upon request.  Biological data is also available for some compounds. 
Before docking, the DTP database was filtered to remove non-drug-like 
compounds.  Using the software program Filter (OpenEye Software), compounds were 
chosen that met the conditions in Table 5.1 and were within the default parameters set for 
elements and functional groups (see Appendix A).  Approximately 23,000 compounds 
Table 5.1  Filter conditions     
  Property Min. Max. 
 Molecular Weight 100 900 
  Rings 2 12 
  Carbons 5 None 
  Rotatable Bonds 0 8 
  H-bond Donors 0 10 
  H-bond Acceptors 2 10 
  Formal Charge (absolute value) 0 2 
  Partition Coefficientŧ 0 8 
  Polar Surface Area 0 140 
 
ŧ XlogP value calculated as the octanol/water partition [1]. 
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met these criteria. 
Each of the 23,000 remaining compounds was docked into the binding pocket of 
the RXR LBD crystal structure [3], in which position 268, 271, 272, 310, 313, and 436 
were changed to alanines.  This is the largest possible binding pocket (229 Å3 larger than 
the wild-type pocket [4]) for a library with the standard L, I, V, F, M, A, S, and T amino 
acid possibilities at each of the six positions.  Of the 23,000 compounds docked, 16,490 
fit in the binding pocket with energy scores ranging from +11 to -25 kcal mol-1.  The 
docking calculation took an average of 30 seconds of CPU time per compound, totaling 8 
days of CPU time on one 195 MHz MIPS R10000 processor of an SGI Octane. 
The compounds with the 100 lowest scores were evaluated.  From this set, OPBA 
was chosen as the first target compound (Figure 5.1).  OPBA is a commercially available 
compound that has a carboxylate analogous to the 9cRA carboxylate.   The pyrene ring 
system makes this compound fluorescent, which should be useful for future binding 
studies.  OPBA is also not known to bind any member of the nuclear receptor family. 
Like 9cRA and LG335, OPBA has a negatively charged carboxylate.  However, 
OPBA is a flat molecule with the aromatic pyrene conjugated to the carbonyl, while 




Figure 5.1  γ-oxo-1-pyrenebutyric acid 
(OPBA). 
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that the cis bond forces the conjugated alkene chain out of plane with the β-ionone ring 
(Figure 4.5).  For LG335, the docking calculations presented in Chapter 4 show that the 
two phenyl rings are forced out of plane due to steric clash with the n-propyl group 
(Figure 4.5).  OPBA is also more hydrophobic than both 9cRA and LG335.  The logP 
value for OPBA is 4.24 compared to 6.83 and 8.56 for 9cRA and LG335, respectively (as 
calculated by LogP DB (Advanced Chemistry Development)). 
 
Library Design and Selection 
The library used to find receptors for OPBA is the same library discussed in 
Chapter 4.  In addition to SC -Ade -Trp -Leu plus 10 µM LG335 medium, approximately 
110,000 (three 24 cm × 24 cm plates) of the 450,000 transformants were replica-plated 
onto SC -Ade -Trp -Leu plus 10 µM OPBA medium and grown at 30 °C for 3 days.  
Forty-seven colonies grew on these three plates.  These colonies were picked and stored 
in 96-well plates at -80 °C in SC -Trp -Leu with 15% glycerol. 
 
High Throughput Screening 
 For initial screening for activation by OPBA, a subset of 167 transformants were 
selected from the 1000 LG335 activated transformants (Chapter 4) and the 47 
transformants that grew on the SC -Ade -Trp -Leu plus 10 µM OPBA medium (see 
above) for initial screening for activation by OPBA.  This is 17% of the transformants 
from this library that grew on solid selective media.  These transformants were inoculated 
into 96-well plates containing SC -Ade -Trp -Leu medium with 10 µM OPBA.  Yeast 
growth in each well was monitored by change in optical density at 630 nm between 0 and 
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39 hours. 
 Based on the results of the initial high-throughput screen, ten transformants were 
chosen for additional screening for OPBA activation.  These ten transformants had an 
∆OD630 of greater than 0.300 in SC -Ade -Trp -Leu medium with 10 µM OPBA, but did 
not show significant growth in SC -Ade -Trp -Leu medium. Of the ten transformants, 
four were originally from LG335 selective plates and six were from OPBA selective 
plates.  These transformants were grown in SC -Ade -Trp -Leu liquid medium without 
ligand and with 0.1, 1, and 10 µM OPBA at 30 °C.  After 39 hours of growth three 
transformants proved to be constitutively active.  The other seven transformants proved 
to be activated by OPBA, two of which grow with 1 µM OPBA (Figure 5.2).  The 
plasmids from these two transformants were rescued, sequenced, and retransformed to 
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Figure 5.3  Selection (A) and screening (B) of RXR variants A272S;I310V;F313M and A272T;I310L;F313T.  The variants were 





 Chemical complementation selection (adenine selection) and screening (β-
galactosidase assay) were used to characterize the activation profiles of these RXR 
variants (Figures 5.3 and Table 5.2).  Wild-type RXR and Gal4, a ligand 
independentyeast transcription factor, were used as controls.  Both variants 
A272S;I310V;F313M and A272T;I310L;F313T are activated by OPBA, but not 
significantly activated by 9cRA. 
 Chemical complementation selection (adenine selection) and screening (β-
galactosidase assay) were used to characterize the activation profiles of these RXR 
variants (Figures 5.3 and Table 5.2).  Wild-type RXR and Gal4, a ligand independent 
yeast transcription factor, were used as controls.  Both variants A272S;I310V;F313M and 
A272T;I310L;F313T are activated by OPBA, but not significantly activated by 9cRA. 
Table 5.2 EC50 and Efficacy for RXR Variants   
  9cRA OPBA 
  Variant EC50§ Eff** EC50 Eff 
  (µM) (%) (µM) (%) 
  WT 0.1 100 70 20 
  A272S;I310V;F313M >100 10 2 100 
  A272T;I310L;F313T >100 0 3 80 
 
§
 EC50, concentration of ligand producing half maximal activity.  
Values represent averages of two screen experiments in 
quadruplicate. 
**
 Eff., efficacy, maximum increase in activation relative to the 
increase in activation of wild type with 10 µM 9cRA.  Values 




 OPBA was computationally docked into the variants using RXR LBD-9cRA 
crystal structure [3] and the InsightII module Affinity.  The two variants were created in 
silico with the Biopolymer module’s residue replacement feature.  The side chains (past 
the β-carbon) of the replaced residues were energy minimized.  Docking was 
accomplished using Monte Carlo simulation.  Simulated annealing was performed on the 
resulting structures to optimize the docked ligand placements. 
 
Discussion 
 From a library of 450,000 RXR variants, two variants were discovered that are 
able to bind and be activated by OPBA, a compound not previously known to activate 
any nuclear receptor.  The combination of chemical complementation selection and 
screening assays on both solid and liquid media proved to be an effective method for 
finding active receptors by zeroing in on the most active and sensitive receptors. 
 Both variants A272S;I310V;F313M and A272T;I310L;F313T have wild-type like 
efficacies in response to OPBA (Table 5.2 and Figure 5.3).  However, the EC50s of the 
variants are 20 and 30 fold greater than the EC50 of wild-type RXR with 9cRA. While 
EC50s greater than wild-type are not ideal, these variants still represent an advance in 
engineering receptors to bind new small molecules.  The hydrophobic pyrene group is 
readily bound in cell membranes [5] and fatty acid derivatives including 1-pyrenebutyric 
acid are often used as fluorescent membrane probes.  Therefore, finding receptors that are 
more sensitive to OPBA may be challenging.  
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B 
Figure 5.4  Structures generated by docking calculations for (A) 
A272S;I310V;F313M and (B) A272T:I301L;F313T. 
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The docking calculations indicate possible binding modes for OPBA in the two 
RXR variants (Figure 5.4).  The butyl chain of OPBA is 3 carbons shorter that 9cRA 
between the methyl group on carbon 9 and the carboxylate.  A large amino acid side 
chain at position 313 could sterically clash with the pyrene moiety of OPBA.  For 
A272S;I310V;F313M, the methionine at position 313 may be having this effect.  
However for this variant, the serine at position 272 may interact with the OPBA 
carboxylate in an alternate binding mode as shown in Figure 5.4A.  For 
A272T;I310L;F313T, a small amino acid at position 313 seems to allow enough space for 
the pyrene group to position the OPBA carboxylate close to R316, Q275, and the 
backbone hydrogen of A327 (Figure 5.4B).  The hydroxyl group of T313 may also be 
involved in stabilization of the OPBA carboxylate. 
High-throughput docking calculations to identify potential ligands were effective 
for selecting a compound that eventually became a ligand.  This method could be useful 
for selecting near-drugs with desirable ADMET properties when developing ligand-
receptor pairs for gene therapy.  Compounds that do not interfere with other biological 
processes and that can reach the desired site of action could be compiled into a database.  
Compounds from this database could then be selected as potential ligands using in silico 
screening based on their compatibility with the library of receptors.  Chemical 
complementation could then be used to select the receptor that best fits the ligand. 
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Materials and Methods 
Compounds 
9cRA was purchased from BIOMOL (Plymouth Meeting, PA).  LG335 [6] was 




pGBDRXR:3Stop [7], pGAD10BAACTR [8, 9], pGBT9Gal4, and  
pGBDRXRαL-SH-ME [10] have been described. 
 
Randomized Cassette Library Construction, Transformation, and Genotype 
Determination 
 The randomized insert cassette was constructed, transformed into PJ69-4a, and 
genotyped as described in Chapter 4. 
 
High-Throughput Selection 
 A set of 164 transformants and yeast containing the plasmids pGBDRXRαL-SH-
ME and pGBDT9Gal4 (all with pGAD10BAACTR) were grown in wells of 96-well 
plates with 200 µL of SC -Trp -Leu medium for 22 hours at 30 °C with shaking.  From 
these plates 20 µL of culture from each well was used to inoculate 96-well plates 
containing 180 µL of SC -Ade -Trp -Leu medium with 10 µM of 9cRA, LG335, or 
OPBA or SC -Trp -Leu medium.  These plates were incubated at 30 °C for 39 hours.  The 
change in optical density at 630 nm was monitored at 18, 24, and 39 hours. 
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Dose Response Quantification 
 Ten transformants were selected from the high-throughput selection assay for 
further analysis.  SC -Trp -Leu medium was inoculated with each transformant and 
incubated at 30 °C with shaking.  The yeast were washed twice with sterile water and 20 
µL was used to inoculate 180 µL of SC -Ade -Trp -Leu medium in 96-well plates with 
0.1, 1, and 10 µM OPBA or without ligand in triplicate.  These plates were grown at 30 
°C with shaking (150 rpm).  Optical density at 630 nm was used to monitor the yeast 
growth over 39 hours. 
 
Liquid Quantification Assay 
 The protocol for the liquid quantification selection and screen assays is described 
in Chapter 4. 
 
Docking Calculations 
 All calculations were run on an SGI Octane MXI with dual 195 MHz MIPS 
R10000 processors and 1 GB of RAM.  
 
FlexX 
 The 3-D DTP database was obtained from the National Cancer Institute 
(dtp.nci.nih.gov).  Drug-like compounds were selected using Filter (OpenEye Scientific 
Software).  Compounds were selected if they met the criteria in Table 5.1 and the 
program's default elemental and functional group criteria (Appendix A).  The structures 
were then separated into individual .mol2 files using InsightII (Accelrys). 
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 The RXR LBD-9cRA crystal structure [3] was modified at positions 268, 310, 
313, and 436 to alanine using the residue replace function of the InsightII module 
Biopolymer.  The protein's coordinates were saved in .pdb format and the 9cRA structure 
was saved in .mol2 format.  FlexX was used to define the binding pocket atoms and 
surface using the coordinates of the carboxylate carbon as the probe location.  The 23,000 
structures were docked using the dock_list batch file available in the FlexX user guide.  
See Chapter 1 for a complete description. 
 
Affinity 
      Docking of OPBA into modified binding pockets was done using the InsightII 
module Affinity.  The wild type RXR with 9cRA crystal structure [3] was modified 
using the Biopolymer module residue replace tool to make mutations in the binding 
pocket that corresponded to the mutations in variants A272S;I310V;F313M and 
A272T;I310l;F313T.  The ligand was placed in the binding pocket by superimposing the 
OPBA onto 9cRA in the crystal structure.  A Monte Carlo simulation with an energy 
range acceptance of 10 kcal mol-1 was performed first, followed by Simulated Annealing 
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 Yeast can serve as a good model system for mammalian cells.  Yeast are easy and 
inexpensive to culture and there are multiple selective markers and reporter genes 
available.  Plasmids can also be easily transformed into and rescued from yeast.  
However, unlike mammalian cells, yeast have a cell wall, which, in conjunction with a 
cell membrane enriched with the steroid ergosterol decrease the penetrability of small, 
drug-like molecules.    
 Several attempts have been made to increase the permeability of yeast.  
Disruption of two endogenous genes has been used to influence intracellular ligand 
concentration.  First, yeast express ATP-binding cassette (ABC) transporters.  A member 
of this class, Pdr5p, is known to selectively transport steroid hormones out of yeast, 
thereby decreasing the intracellular hormone concentration [1].  When Pdr5p is knocked-
out or inhibited by FK506 [2],  the concentration of hormone within the yeast cells is 
consequently increased.  Second, yeast strains have been engineered with an ERG6 
knockout.  ERG6 is an essential gene in the ergosterol biosynthetic pathway and without 
this gene, the permeability of the yeast cell membrane by small molecules is enhanced 
[3]. 
 Small molecules and peptides like amphotericin B (AmB) and polymixin B 
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nonapeptide (PBN) have also been shown to increase the permeability of yeast to a 
variety of antibiotics including rifampicin.  AmB is hypothesized to interact with 
ergosterol in the yeast cell membrane to form a cage [4].  These cages disorder the cell 
membrane and may create pores, thereby increasing permeability of the cell membrane to 
cationic antibiotics.  PBN, a circular peptide, induces a similar increased sensitivity to 
some antibiotics [5].  However, not all of the antibiotics tested by Boguslawski had 
increased efficacy, indicating that the effect of this peptide is not a general increase in 
membrane permeability.       
 The EC50s of the ligand-receptor pairs discussed in this thesis are expressed in 
terms of the ligand concentration in the media.  Because of permeability concerns with 
the yeast, a method was developed to determine the intracellular ligand concentration.  
This method uses LC-MS/MS to determine the concentration of ligand in cell lysates.  
When compared to a standard curve the intracellular concentration can be determined.    
 The yeast were grown with and without 10 µM LG335 overnight (see Materials 
and Methods for details).  The cells were washed, then lysed with boiling MeOH and 
sonicated.  The cell debris was removed by centrifugation.  The supernatant and the final 
cell wash were lyophilized, and the residue was rehydrated in fifty times the yeast 
volume of 95:5 H2O:MeOH with 1% (v/v) formic acid.  High-performance liquid 
chromatography (HPLC) was coupled by electrospray ionization with multiple reaction 
monitoring (MRM) using a triple quadrupole mass spectrometer for detection.  The first 
quadrupole allows only ions with a mass of 379 amu (M+H) to pass.  The second 
quadrupole is used as a fragmentation chamber.  The third quadrupole is used to select 
ions with a mass of 149 amu (the most abundant fragment) of LG335.  Thus, only 
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compounds with a specific molecular weight that fragment to produce a specific product 
ion are detected.  Standards from 100 nM to 10 µM LG335 were used to generate a 
standard curve (Figure 6.1).  Samples (cell lysates and the final wash) and standards were 
injected in triplicate and the experiment was duplicated.  The limit of detection of LG335 
using this technique is 100 nM.  Peaks are detected if they are greater than ten counts 
above baseline and the area under the curve (AUC) is greater than five.  Below 100 nM 
LG335, not peak was detected.  The average AUC of three injections was used to 
calculate a concentration, which was then multiplied by 50 to reflect the actual 
intracellular concentration.  The intracellular concentration of LG335 was found to be 20 
and 40 µM in the two trials, respectively.  No ligand was detected in the final wash, 
signifying that the LG335 detected is from inside the yeast cells.  The results of these 
experiments show that the intracellular concentration of LG335 is within four-fold of the 
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Figure 6.1  LG335 quantification standard curve.  Trial 1 (red circles) and Trial 2 
(blue squares) were fitted with linear regression lines (red and blue respectively).  
Trail 1 sample (open circle) and Trial 2 sample (closed square). 
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Materials and Methods 
 
Lysate Preparation Method 
 Cultures of PJ69-4A were grown in 5 mL of synthetic complete (SC) media with 
and without 10 µM LG335 for 24 hours at 30º with shaking.  The cultures were then 
centrifuged and the media was removed.  The cells were washed four times with 1:10 TE.  
The number of yeast cells was determined by measuring optical density at 600 nm with a 
BioPhotometer (Eppendorf) after resuspension in 1:10 TE for the final time.  The 
conversion factor of 3 × 106 cells per 0.1 OD600 was used to determine the total number 
of cells.  The total cell volume was determined by using the average cell volume of 70 
µm3 [6].  The final wash was saved.  The cells were then lysed by boiling in MeOH for 
10 minutes followed by 10 minutes of sonication [7, 8].  The cell debris was removed by 
centrifugation at 3500 g for 10 minutes.  The supernatant and the final 1:10 TE washes 
were evaporated by vacuum centrifugation.  Each sample and the corresponding washes 
were resuspended in 50 times the total cell volume.   
 
Liquid Chromatography Method 
High-performace liquid chromatography was performed on an Agilent 1100 
HPLC with binary pumps.  The separations were done on a 5 cm × 1 mm Discovery® HS 
F5 3 µm column (Supelco).  Solvent A was 95:5 H2O:MeOH with 1% CHOOH and 
solvent B was 5:95 H2O:MeOH with 1% CHOOH .  The gradient consisted of 2 minutes 
with 100% solvent A, an 8 min gradient to 100% solvent B, 5 minutes at 100% solvent B, 
and reequilibration to 100% solvent A for 5 minutes with a flow rate of 150 µL per 
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minute.   The samples were injected via autosampler in 50 µL volumes. 
 
Mass spectrometry method 
The HPLC was coupled to a Quattro LC (Micromass) triple quadrupole mass 
spectrometer.  The mass spectrometer was operated with an electrospray ionization 
source in positive mode (ESI+) using multiple reaction monitoring (MRM).  The 
transition monitored for LG335 was 379 → 149 amu.  The desolvation and ion source 
temperatures were 250 ºC and 100 ºC respectively with a cone voltage of 25.9 eV.  
Fragmentation occurred in the second quadrupole with collision energy of 35 eV and 2.9 
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 The goal of this research was to develop a strategy for engineering receptors that 
bind arbitrary small molecules.  Using a combination of molecular modeling, library 
design, and chemical complementation, receptors that bind and are selectively activated 
by two new compounds, LG335 and OPBA, were created and discovered.  In the course 
of this research several techniques and methods were developed including a new 
synthesis route for LG335, ligand-protein docking protocols for two software programs, 
protein library design and construction, and high-throughput and variable stringency 
chemical complementation.  
Ligand binding to RXR causes specific conformational changes that allow 
recruitment of coactivators and the transcription machinery.  The interactions in the 
binding pocket between the ligand and protein atoms facilitate the conformational change 
and therefore, must be precise.  Because the ligand-protein interactions required for the 
correct conformational change are not yet understood, direct design of receptors that are 
activated by specific ligands is extremely difficult.  Creating a library of proteins with 
mutations at specific positions in the binding pocket, and using chemical 
complementation to select active variants allows the protein to determine the best fit.  
Libraries were designed based on structural and functional knowledge of RXR.  By 
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randomizing hydrophobic amino acids in the binding pocket, the shape and size of this 
pocket were altered allowing for selective binding of new ligands.  This process was used 
to find receptors for two ligands, LG335 and OPBA. 
LG335 is similar in structure the known RXR agonist bexarotene (Targretin®).  
The synthetic yield of LG335 was improved to 8% from 4% in original publication by 
altering the synthetic route [1, 2].  The inclusion of polar amino acids in the library 
proved essential for discovering receptors with high efficacy and low EC50s for LG335.  
This may be due to an alteration of the hydrophobicity of the binding pocket, which 
makes binding of the less hydrophobic molecule LG335 more favorable than the more 
hydrophobic wild-type ligand 9cRA. 
OPBA was chosen as a potential ligand using high-throughput docking.  Two 
receptors for this ligand were discovered.  These receptors have wild-type-like efficacies, 
but the EC50s are 20 to 30 fold greater than wild-type RXR with 9cRA.  Both receptors 
have mutations to polar amino acids in the center of the binding pocket.  These amino 
acids may be required to stabilize the carboxylate because the butyl chain may not be 
long enough to bring the carboxylate in contact with the positively charged end of the 
pocket.   
Chemical complementation [3, 4] is a versatile method that can be used both for  
genetic selection and as a functional screen.  The genetic selection capability of chemical 
complementation on solid media can be used for initial selection of functional variants.  
Receptors among the surviving pool that have desired properties can then be analyzed 
using chemical complementation in liquid media.  Variable stringency chemical 
complementation uses the histidine selective marker and 3AT to tune the activation 
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threshold level required for yeast growth in response to ligand.  This method allows 
targeting of variants with high efficacies.  Decreasing the concentration of ligand present 
in selective media allows targeting of variants with low EC50s.  High-throughput 
chemical complementation can be used to identify variants that are activated by specific 
ligands.  Replicating 96-well plates in liquid medium containing different ligands can 
quickly differentiate receptors that show selectivity in activation versus variants that are 
promiscuous (activated by multiple ligands) or constitutively active.  
 As a functional selection and screen, chemical complementation can be used to 
determine efficacy and EC50.  Chemical complementation in selective liquid medium 
responds as a switch; once transcription of the selective marker (HIS3 or ADE2) reaches 
the growth threshold, full growth occurs.  A better reporter of transcription, and therefore 
a better indicator of efficacy and EC50, is the β-galactosidase assay.  This assay measures 
the activity of β-galactosidase, which correlates to the transcription level of the LacZ 
gene. 
 When characterizing individual RXR variants, EC50s and efficacies are calculated 
according to the concentration of ligand in the medium.  These values are only correct if 
the intracellular ligand concentration is equal to the concentration of ligand in the 
medium.  An LC-MS/MS method was developed to quantify intracellular concentrations.  
The intracellular concentration of LG335 was determined to be within four fold of the 
LG335 concentration in the medium. 
 In silico ligand-protein docking is a useful tool for generating hypotheses 
concerning the placement and interaction of specific ligands with specific RXR variants.  
However, due to insufficiencies in the force field and docking method, the energies 
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between different receptor variants and/or ligands do not correlate with experimental 
data.   
 
Future work 
During the course of this research nine constitutively active RXR variants were 
sequenced that had base insertions or deletions resulting in shifted reading frames.  The 
frame shift for these nine variants results in truncation of the protein due to an in-frame 
stop codon at position 319.  These proteins are terminated between helix 5 and sheet 1 
with a protein that is 143 amino acids shorter than the full RXR LBD.  Since this new 
protein does not contain a complete ligand-binding pocket or the activation function 
domain 2 (AF2) normally necessary for RXR to be active, the activity of these truncated 
proteins is unexpected.  It is possible that this new protein is able to interact with the 
yeast transcription machinery independently of ligand or ACTR.  To test this hypothesis, 
each of the nine variants could be transformed into PJ69-4A without pGAD10BAACTR.  
These variants could also be tested in mammalian cell culture to determine if the 
constitutive activity of these variants is specific to yeast.  A subset of these proteins 
should also be expressed, purified, and the molecular weight and amino acid sequence 
determined to ensure that these proteins are truly truncated.    
 A variant (I268A;A271V;G304V;F313M;∆13) in an early library also had base 
deletions that resulted in a frame shift termed ∆13.  A one base deletion followed by 37 
RXRwt -   HLFFFKLIGDTPIDT 
RXR∆13 -  HTSSSSSSGTHQL T 
 
Figure 7.1  Sequence changes between wild-type RXR 
and I268A;A272V;G304V;F313M;∆13 
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bases and a two base deletion results in 13 amino acid changes (Figure 7.1).  These 
changes occur from helix 11 to helix 12 preceding the AF2 domain, which remains intact.  
This variant is activated by LG335 with an EC50 of approximately 200 nM (Figure 7.2).  
Further investigation of the mutations in this variant is warranted.  First, the ∆13 set of 
mutations could be incorporated into wild-type RXR independent of the other mutations 
to determine if these changes have any effect of the activation of wild-type RXR with 
9cRA and/or LG335.  The G304V mutation may also be interesting.  The glycine at 
position 304 causes a break between helices 4 and 5.  A valine at this position may stiffen 
the connection between helix 4 and 5 resulting in a slight repositioning of helix 5.  Helix 
5 is one of the helices that define the RXR binding pocket and a change in the position of 
this helix may affect ligand binding.  
The overall yield of the new synthesis route for LG335 could be improved by 
optimizing the final deprotection step.  This reaction has a previously published yield of 
93% [1].  If a yield of 93% could be obtained for this final reaction, the overall yield 
would improve from 8% to 20%. 
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FILTER DEFAULT PARAMETERS 
 
 
#This file defines the rules for filtering multi-structure files based on  
#properties and substructure patterns. 
#NOTE: this rule file is suitable for drug-like filtering and may be 
# too restrictive for reagent filtering. 
#These rules include the contributions of countless chemists & modellers including: 
#Rule of 5:   
# Lipinski, C, et al., Adv.Drug Deliv. Rev., 23:3, 1997. 
#General Filtering: 
# Oprea, T., JCAMD 14:251-264, 2000. 
#XLogP: 
# Wang, R, Ying, Fu, & Lai, Luhua, J.Chem. Inf. Comput. Sci., 37:615-621, 1997. 
#Polar Surface Area 
# Peter Ertl, Bernhard Rohde, & Paul Slzer, J. Med. Chem. 43:3714-3717, 2000. 
# David E. Clark, Journal of Pharmaceutical Sciences, 88(8):807-814, 1999. 
 
MIN_MOLWT   100      "Minimum molecular weight" 
MAX_MOLWT   900      "Maximum molecular weight" 
 
MIN_SSSR_RINGS   2 "Minumum number of SSSR rings" 
MAX_SSSR_RINGS   7 "Maximum number of SSSR rings" 
 
MAX_RING_SIZE   12 "Maximum size of any SSSR ring" 
 
MIN_CARBONS   5 "Minimum number of carbons" 
MIN_HETEROATOMS  0 "Minimum number of heteroatoms" 
MIN_Het_C_Ratio   0 "Minimum heteroatom to carbon ratio" 
MAX_Het_C_Ratio   1.0 "Maximum heteroatom to carbon ratio" 
   
 
#count ring degrees of freedom = (#BondsInRing) - 4 - (RigidBondsInRing) - 
(BondsSharedWithOtherRings) 
#must be >= 0, from JCAMD 14:251-265,2000. 
ADJUST_ROT_FOR_RING true   "BOOLEAN for weather to estimate 
degrees of freedom in rings" 
 
MIN_ROT_BONDS   0 "Minimum number of rotatable bonds" 
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MAX_ROT_BONDS   8 "Maximum number of rotatable bonds" 
 
MIN_RIGID_BONDS  8 "Minimum number of rigid bonds" 
MAX_RIGID_BONDS  50 "Maximum number of rigid bonds" 
 
MIN_HBOND_DONORS  0 "Minimum number of hydrogen-bond 
donors"   
MAX_HBOND_DONORS  10 "Minimum number of hydrogen-bond 
donors"   
 
MIN_HBOND_ACCEPTORS 2 "Minimum number of hydrogen-bond 
acceptors"   
MAX_HBOND_ACCEPTORS 10 "Minimum number of hydrogen-bond 
acceptors"   
 
MIN_COUNT_FORMAL_CRG 0 "Minimum number formal charges" 
MAX_COUNT_FORMAL_CRG 3 "Maximum number of formal charges" 
MIN_SUM_FORMAL_CRG  0 "Minimum sum of formal charges" 
MAX_SUM_FORMAL_CRG 2 "Maximum sum of formal charges" 
 
MIN_XLOGP    0.0 "Minimum XLogP" 
MAX_XLOGP   8.0 "Maximum XLogP" 
 
MIN_2D_PSA   0.0 "Minimum 2-Dimensional (SMILES) Polar 
Surface Area" 
MAX_2D_PSA   140.0 "Maximum 2-Dimensional (SMILES) Polar 
Surface Area" 
 
ALLOWED_ELEMENTS H,C,N,O,F,S,P,Cl,Br,I  
 
#acceptable molecules must have <= instances of each of the patterns below 
 
#specific undesirable functional groups 
RULE 0 Carbazides 
RULE 0 Acid_anhydrides 
RULE 0 Pentafluorophenyl_esters 
RULE 0 Paranitrophenyl_esters 
RULE 0 HOBT_esters 
RULE 0 Triflates 
RULE 0 Lawesson_s_reagent 
RULE 0 Phosphoramides 
RULE 0 Aromatic_azides 
RULE 0 Beta_carbonyl_quart_nitrogen 
RULE 0 Acylhydrazide 
RULE 0 Quarternary_C_Cl_I_P_or_S 
RULE 0 Phosphoranes 
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RULE 0 Chloramidines 
RULE 0 Nitroso 
RULE 0 P_S_Halides 
RULE 0 Carbodiimide 
RULE 0 Isonitrile 
RULE 0 Triacyloxime 
RULE 0 Cyanohydrins 
RULE 0 Acyl_cyanides 
RULE 0 Sulfonyl_cyanides 
RULE 0 Cyanophosphonates 
RULE 0 Azocyanamides 
RULE 0 Azoalkanals 
RULE 0 Polyenes 
RULE 0 Saponin_derivatives 
RULE 0 Cytochalasin_derivatives 
RULE 0 Cycloheximide_derivatives 
RULE 0 Monensin_derivatives 
RULE 0 Cyanidin_derivatives 
RULE 0 Squalestatin_derivatives 
 
#functional groups which often eliminate compounds from consideration 
RULE 0 acid_halide 
RULE 0 aldehyde 
RULE 0 alkyl_halide 
RULE 0 anhydride 
RULE 0 azide 
RULE 0 azo 
RULE 0 di_peptide 
RULE 0 long_aliphatic_chain   //(>7 atoms) 
RULE 0    michael_acceptor 
RULE 0 beta_halo_carbonyl 
RULE 0    nitro 
RULE 0 peroxide 
RULE 0 phosphonic_acid 
RULE 0 phosphonic_ester 
RULE 0 phosphoric_acid 
RULE 0 phosphoric_ester 
RULE 0 sulfonic_acid 
RULE 0 sulfonic_ester 
RULE 0    triphenyl_phosphene 
RULE 0 unbranched_chain    //(>4_atoms) 
RULE 0 epoxide 
RULE 0 hetero_hetero 
RULE 0 sulfonyl_halide 
RULE 0 halopyrimidine 
RULE 0 perhalo_ketone 
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RULE 0 methyl_ketone 
RULE 0 aziridine 
RULE 0 imine 
RULE 0 oxalyl 
 
#the dye group includes a set of patterns which describe all cpds with colors in their 
names from the ACD98.2 
 
RULE 0 dye 
  
#functional groups which are allowed, but may not be wanted in high quantities 
#common functional groups 
 
RULE 6 alcohol 
RULE 4 alkene 
RULE 4 amide 
RULE 4 amino_acid 
RULE 4 amine 
RULE 4 primary_amine 
RULE 4 secondary_amine 
RULE 4 tertiary_amine 
RULE 4 carboxylic_acid 
RULE    1       halide 
RULE 1 iodine 
RULE 4 ketone 
RULE 4 phenol 
 
#other functional groups 
 
RULE 4 alkyne 
RULE 4 aniline 
RULE 4 aryl_halide 
RULE 4 carbamate 
RULE 4 ester 
RULE 4 ether 
RULE 4 hydrazine 
RULE 4 hydrazone 
RULE 4 hydroxylamine 
RULE 4 nitrile 
RULE 4 sulfide 
RULE 4 sulfone 
RULE 4 sulfoxide 
RULE 4 thiourea 
RULE 4 thioamide 
RULE 4 thiol 
 
